---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence. Covers NATiV3, NATIVE, LEGEND, and NCT03459079. 313 evidence topics quoted from 54 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 NATiV3

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Primary objectives of Part A and Part B in the ClinicalTrials.gov record

> “This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage F2 or F3 and consists of 2 sequential parts - an initial double-blind placebo-controlled (DBPC) period (Part A) followed by a double-blind active treatment extension (ATE) period (Part B), with the following primary objectives:”
> “Part A To assess the safety and efficacy of lanifibranor compared to placebo on 'NASH resolution and improvement of fibrosis' assessed by liver histology.”
> “Part B To assess the safety of lanifibranor beyond the DBPC period.”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.1-2"></a>

###### Key secondary and other secondary objectives in the ClinicalTrials.gov record

> “To assess the effect of lanifibranor compared to placebo on NASH resolution and no worsening of fibrosis”
> “To assess the effect of lanifibranor compared to placebo on improvement of fibrosis with no worsening of NASH”
> “To assess the effect of lanifibranor on NASH resolution and improvement of fibrosis in diabetic patients (only for DBPC period)”
> “To assess the effect of lanifibranor on liver stiffness and steatosis assessed by elastography.”
> “To assess the effect of lanifibranor on health-related quality of life”
> “To assess population PK modeling through plasma levels of lanifibranor using sparse sampling scheme (only for DBPC period)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.1-3"></a>

###### Main objective in the EU Clinical Trials Information System record

> “The primary objectives of both periods in the main cohort are: • Double-blind placebo-controlled (DBPC) period (Part A) To assess the effect of lanifibranor compared to placebo on NASH resolution and improvement of fibrosis assessed by liver histology. • Double-blind active treatment extension (ATE) period (Part B) To assess the safety of lanifibranor beyond the DBPC period.”

Source: [EU Clinical Trials Information System 2023-508248-23-00](https://euclinicaltrials.eu/ctis-public/view/2023-508248-23-00)

<a id="topic-3.1.1.1-4"></a>

###### Aim of the trial stated by the company in September 2026

> “NATiV3 is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the long-term efficacy and safety of lanifibranor (800mg/daily and 1200mg/daily) in 1009 adult patients with biopsy-proven non-cirrhotic MASH and F2/F3 stage of liver fibrosis.”
> “The effect of lanifibranor will be assessed on several histological endpoints, including MASH resolution and improvement of fibrosis of at least one stage after 72 weeks of treatment.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.1-5"></a>

###### Primary objectives of Part 1 and Part 2 in the original ClinicalTrials.gov record, April 2021, superseded in March 2023

> “This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis stage 2 or 3 and consists of 2 parts - Part 1 and Part 2, with the following primary objectives:”
> “Part 1 To assess the effect of lanifibranor compared to placebo on NASH resolution and improvement of fibrosis assessed by liver histology.”
> “Part 2 To assess the effect of lanifibranor compared to placebo on delaying NASH disease progression measured by a composite endpoint that includes progression to cirrhosis, liver-related clinical outcome events, or all-cause death.”
> “To assess the long-term safety (up to 7 years) of lanifibranor”

Source: [ClinicalTrials.gov NCT04849728 version 1](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=1)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2021-08-19”
> “Primary Completion (Actual) 2026-09-29”
> “Study Completion (Estimated) 2027-09-30”
> “First Posted 2021-04-19”
> “Last Update Posted 2026-11-02”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.2-2"></a>

###### Number of locations in the ClinicalTrials.gov record

> “This study has 459 locations”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.2-3"></a>

###### EU member states, trial start, and estimated end of trial in the EU Clinical Trials Information System record

> “Locations Italy, Czechia, Hungary, Bulgaria, Spain, Belgium, Poland, Germany, Portugal, France, Netherlands”
> “Start of trial 26/11/2021”
> “Estimated recruitment start date in EU/EEA: 19/01/2022”
> “Estimated end of trial date in EU/EEA: 12/12/2026”
> “Estimated global end date of the trial: 13/12/2026”

Source: [EU Clinical Trials Information System 2023-508248-23-00](https://euclinicaltrials.eu/ctis-public/view/2023-508248-23-00)

<a id="topic-3.1.1.2-4"></a>

###### Activation of the first sites in the United States, September 2021

> “The first clinical trial sites have been activated in the United States and first patients have been screened.”
> “In addition, more than 330 sites across 25 countries have already been qualified2 of which more than a third in the United States.”

Source: [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf)

<a id="topic-3.1.1.2-5"></a>

###### Sites, countries, and regional distribution of randomized participants, December 2023

> “As of December 20, 2023, 468 clinical sites have been activated in 24 countries, including China, and a total of 793”
> “Approximately 70% of the patients randomized in the main and exploratory cohorts are from the United States, ~20% from Europe and ~10% from Latin America and the rest of the world.”

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf)

<a id="topic-3.1.1.2-6"></a>

###### Initiation, sites in Ukraine and Russia, China participation, and completion of screening and randomization stated in the Form 20-F

> “In September 2021, we initiated our NATiV3 Phase III clinical trial of lanifibranor in MASH. We completed randomization of the last patient in NATiV3 in April 2025.”
> “For example, in 2022, we put recruitment for our NATiV3 trial on hold in Ukraine and removed all of the planned sites in Russia from the NATiV3 trial due to the Russian invasion in Ukraine”
> “In December 2023, we announced that our licensee CTTQ, who joined our NATiV3 trial, randomized the first patient in China”
> “In January 2025, the Company completed screening of patients in the ongoing NATiV3 trial.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.2-7"></a>

###### Last patient visit of the 72-week treatment period, September 2026

> “today announced the last patient has completed their final 72-week visit in the NATiV3 Phase 3 clinical trial”
> “With the last patient having completed their final visit, all patients have completed the 72-week treatment period.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.2-8"></a>

###### Estimated completion dates in the ClinicalTrials.gov record, January 2023, superseded in March 2023

> “Viewing V15 (2023-01-23)”
> “Primary Completion 2024-02 [Estimated]”
> “Study Completion 2028-09 [Estimated]”

Source: [ClinicalTrials.gov NCT04849728 version 15](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=15)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Official title and design details in the ClinicalTrials.gov record

> “A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis Stages F2 and F3”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.3-2"></a>

###### Trial phase and transition status in the EU Clinical Trials Information System record

> “Trial Phase Therapeutic confirmatory (Phase III)”
> “Transition trial Yes”

Source: [EU Clinical Trials Information System 2023-508248-23-00](https://euclinicaltrials.eu/ctis-public/view/2023-508248-23-00)

<a id="topic-3.1.1.3-3"></a>

###### Main cohort, exploratory cohort, and active treatment extension in the company design slide

> “Noncirrhotic MASH and F2-F3 fibrosis”
> “Screen-failed patients from the main cohort”
> “noncirrhotic MASH and F1-F4 fibrosis”
> “All patients who complete the main or the exploratory cohort are eligible for the Phase 3 active treatment extension trial”
> “Stratification by fibrosis stage and diabetic status”
> “NATiV3 fully recruited: trial design mirrors the successful Phase 2b study”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.3-4"></a>

###### Randomization ratio, stratification factors, and amended design stated by the company

> “Patients will be randomized 1:1:1 in placebo and treatment arms (800mg/daily or 1200mg/daily of lanifibranor) and stratified based on their fibrotic stage (F2 and F3) as well as presence or absence of type 2 diabetes (T2DM).”

Source: [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf)

> “The NATiV3 trial, including the amended protocol, has been designed as a double-blind, placebo-controlled global pivotal Phase 3 clinical trial to assess the potential benefit of lanifibranor treatment on liver-related clinical outcomes.”
> “After the pre-specified histological analysis, the trial will remain blinded and all patients randomized in the trial will have access to the active treatment if they decide to continue in a new active 48-week treatment extension study.”
> “A placebo-controlled exploratory cohort has been initiated in parallel to the NATiV3 trial and will include approximately 350 patients with MASH and fibrosis who are not eligible for the NATiV3 trial.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.3-5"></a>

###### Active treatment extension described as double-blind in the registry records

> “Part B: ATE:”
> “48 weeks after completion of DBPC period”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

> “• Double-blind active treatment extension (ATE) period (Part B) To assess the safety of lanifibranor beyond the DBPC period.”

Source: [EU Clinical Trials Information System 2023-508248-23-00](https://euclinicaltrials.eu/ctis-public/view/2023-508248-23-00)

<a id="topic-3.1.1.3-6"></a>

###### Extension described as open-label by the company in September 2026

> “Following completion of the 72-week treatment period, patients participating in NATiV3 had the option to continue into a 48-week open-label extension period, during which all patients, including those originally randomized to placebo, receive active treatment with lanifibranor.”
> “This extension will provide additional information on the longer-term safety of lanifibranor.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.3-7"></a>

###### Exploratory cohort of participants histologically not eligible for the main cohort

> “An exploratory cohort has enrolled 410 patients with MASH and F1 through F4 stage of liver fibrosis.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

> “and in the exploratory cohort, which includes patients with MASH/NASH and fibrosis stage F1 through F4 who are histologically not eligible for the main cohort.”

Source: [Inventiva fourth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-4th-DMC-NATiV3-EN-05-16-2024.pdf)

<a id="topic-3.1.1.3-8"></a>

###### Central biopsy review process developed with regulatory authorities

> “We have decided to replicate several key elements of the previous Phase IIb trial, including using the same patient enrollment screening criteria, and have developed a central biopsy review process in alignment with regulatory authorities.”

Source: [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf)

<a id="topic-3.1.1.3-9"></a>

###### January 2023 protocol amendments replacing Part 2 with a separate outcomes trial in compensated cirrhosis

> “Confirmatory trial of lanifibranor clinical benefits, which was initially planned to be evaluated in Part 2 of NATiV3 trial in patients with NASH and F2/F3 fibrosis, is now planned to be evaluated in a new Phase III trial in patients with NASH and compensated cirrhosis in place of the previously planned Part 2 of the NATiV3 trial”
> “1) reducing the number of biopsies a patient undergoes during the trial from three to two, 2) reducing the trial duration a patient has to consent to from 7 years to 72 weeks, 3) offering all patients in the trial access to a lanifibranor treatment for at least 48 weeks by allowing them to enter into a new active treatment extension study”

Source: [Inventiva clinical development changes release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Changes-clinical-development-of-lanifibranor-EN-01-04-2023.pdf)

> “Under the new trial design, the originally-planned Part 2 of the NATiV3 trial, a clinical outcome trial that was planned to be conducted in approximately 2,000 patients with F2 and F3 fibrosis for a maximum period of seven years, will be replaced by a placebo-controlled Phase 3 outcome trial which will be event driven and is expected to last approximately three years, depending on patient enrollment.”
> “Although the FDA’s guidance during a consultation preceding the January 2023 protocol amendments was to continue our NATiV3 trial as originally planned, the FDA did not object to the January 2023 protocol amendments”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.3-10"></a>

###### Amended design posted in the ClinicalTrials.gov record, March 2023

> “Viewing V16 (2023-03-30)”
> “A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )”

Source: [ClinicalTrials.gov NCT04849728 version 16](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=16)

<a id="topic-3.1.1.3-11"></a>

###### Two-part design with a Part 2 clinical outcomes period in about 2,000 participants, January 2021, superseded in January 2023

> “The trial will remain blinded after the pre-specified histological analysis and continue in a total of approximately 2,000 patients until the occurrence of a pre-specified number of adverse liver-related clinical events, including progression to cirrhosis.”
> “The trial would be completed on a post-marketing basis in the event that accelerated (U.S.) / conditional (EU) approval is received.”

Source: [Inventiva NATiV3 design release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-P3-Design-EN-050121-VF.pdf)

> “Part 2 will follow the 72-week histology analysis and will assess the effect of lanifibranor (800mg/daily and 1200mg/daily) compared to placebo on delaying NASH disease progression measured by a composite endpoint that includes progression to cirrhosis, liver-related clinical outcome events, and all-cause death.”

Source: [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf)

<a id="topic-3.1.1.3-12"></a>

###### Part 2 clinical outcome primary measure in the ClinicalTrials.gov record, January 2023, superseded in March 2023

> “Viewing V15 (2023-01-23)”
> “Time to first clinical outcome event”
> “Histological progression to cirrhosis (defined as histological confirmation of fibrosis score CRN F4)”
> “[Time Frame: Part 2: Date of randomisation until the End of Study (EoS) date approximately 7 years after first patient randomized]”

Source: [ClinicalTrials.gov NCT04849728 version 15](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=15)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Prescreening criteria in the ClinicalTrials.gov record

> “Diagnosed with NASH on prior liver biopsy”
> “Type 2 diabetes with high waist circumference or obesity or hepatic steatosis on ultrasound”
> “At least 3 of the components of metabolic syndrome”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.4-2"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “Male or female, aged ≥18 years at the time of signing informed consent”
> “Upon central biopsy reading process: diagnosis of NASH according to the Steatosis-Activity-Fibrosis (SAF):”
> “Steatosis score ≥1”
> “Activity score: A3 or A4”
> “Fibrosis score: F2 or F3”
> “Antidiabetic treatment if glucagon-like peptide-1 receptor agonists (GLP1 receptor agonists) or sodium-glucose co-transporter-2 inhibitors (SGLT2 inhibitors): for at least 3 months”
> “Vitamin E (if at a dose ≥400 IU/day): for at least 6 months”
> “Weight stable for 6 months prior to Screening and between the qualifying liver biopsy and Baseline (no more than 5% change for both periods)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.4-3"></a>

###### Liver-related exclusion criteria in the ClinicalTrials.gov record

> “Documented causes of chronic liver disease other than NASH”
> “Histologically documented liver cirrhosis (fibrosis stage F4)”
> “ALT or AST >5 × ULN”
> “Haemoglobin <110 g/L (11 g/dL) for females and <120 g/L (12 g/dL) for males”
> “Patient currently receiving any approved treatment for NASH or obesity”
> “Current or recent history (<5 years) of significant alcohol consumption”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.4-4"></a>

###### Glycemic, obesity-related, cardiovascular, and general exclusion criteria in the ClinicalTrials.gov record

> “HbA1c >9% at Screening”
> “Diabetes mellitus other than type 2”
> “Current treatment with insulin”
> “Treatment with PPAR-gamma agonists (thiazolidinediones [TZDs]) 12 months before screening or historical biopsy.”
> “Bariatric surgery: Restrictive procedures are allowed, if performed >6 months prior to the qualifying liver biopsy; malabsorptive procedures and procedures combining both restrictive and malabsorptive methods are not allowed within 5 years of the qualifying liver biopsy.”
> “History of heart failure with reduced left ventricular ejection fraction (LVEF)”
> “Atrial fibrillation requiring anticoagulation”
> “Uncontrolled hypertension at Screening (values >160/100 mm Hg)”
> “Concomitant treatment with PPAR-alpha agonists (fibrates)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.4-5"></a>

###### Concomitant GLP-1 receptor agonist allowed at a stable dose, company design slide

> “Patients under a stable dose of GLP-1-RA for at least 3 months prior to screening can be included”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.4-6"></a>

###### Exclusion of autoimmune liver or thyroid disease added after a suspected unexpected serious adverse reaction, February 2024

> “amendment to the protocol to exclude newly screened patients diagnosed or with a predisposition to autoimmune liver or thyroid disease.”

Source: [Inventiva preliminary full year 2023 results announcement (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-2023-Revenue-et-Cash-EN-02-15-2024-final-1.pdf)

> “Inventiva has lifted the voluntary pause on screening and randomization in the NATiV3 clinical trial following the approval from the US central IRB of the amended protocol and ICF.”

Source: [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf)

> “We decided to voluntarily pause screening and randomization to implement, including based on input from the FDA, changes to the enrollment criteria to exclude patients diagnosed or with a predisposition to autoimmune liver or thyroid disease and more frequent liver monitoring for patients enrolled in the trial as recommended by the Data Monitoring Committee.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Treatment arms and tablets in the ClinicalTrials.gov record

> “Experimental: Lanifibranor (IVA 337) (800 mg/day)”
> “2 Lanifibranor tablets 400mg + 1 Placebo to match tablet with food --> once a day (quaque die, QD)”
> “Experimental: Lanifibranor (IVA 337) (1200 mg/day)”
> “3 Lanifibranor tablets 400mg with food --> once a day (quaque die, QD)”
> “Placebo Comparator: Matching placebo”
> “3 Placebo to match tablets with food --> once a day (quaque die, QD)”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.5-2"></a>

###### Randomization to two lanifibranor doses or placebo stated by the company

> “Patients will be randomized 1:1:1 to receive lanifibranor (800mg once daily or 1200mg once daily) or placebo.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.5-3"></a>

###### Treatment duration of the main and exploratory cohorts and the extension, company design slide

> “72 weeks of treatment”
> “lanifibranor: 1200 mg once daily”
> “lanifibranor: 800 mg once daily”
> “Placebo: once daily”
> “48 weeks”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.5-4"></a>

###### Active treatment with lanifibranor for all participants during the 48-week extension

> “during which all patients, including those originally randomized to placebo, receive active treatment with lanifibranor.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.5-5"></a>

###### Liver monitoring every 6 weeks added for enrolled participants, March 2024

> “Inventiva chose to voluntarily pause screening and randomization of new patients in the NATiV3 trial to implement the recommendations of the independent Data Monitoring Committee”
> “which included liver monitoring every 6 weeks for each patient enrolled in the trial”

Source: [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using MASH Resolution and Fibrosis Improvement of at Least One Stage as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Primary outcome measure as named and defined in the ClinicalTrials.gov record

> “Resolution of NASH and improvement of fibrosis”
> “Part A: DBPC: Resolution of NASH and improvement of fibrosis at Week 72, defined by NASH CRN scores for ballooning of 0 and inflammation of 0 to 1, and fibrosis score ≥1 stage decrease compared to Baseline”
> “Part A: Date of randomisation until the date of biopsy at Week 72”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.6.1-2"></a>

###### Primary endpoint as a composite and the two single histologic endpoints as key secondary endpoints, company wording

> “Primary end point:”
> “Composite end point of patients having both MASH resolution and 1 stage of fibrosis improvement”
> “Key secondary end points:”
> “MASH resolution and no worsening of fibrosis, fibrosis improvement, and no worsening of MASH”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

> “The primary composite endpoint of patients having both NASH resolution and fibrosis improvement of at least one stage will be used for the 72-week histology analysis.”
> “The endpoint is designed to predict a significant improvement of prognostic risk and, if met, may support a label for the treatment of NASH and the improvement in liver fibrosis in adult non-cirrhotic NASH patients.”
> “Endpoints of NASH resolution and no worsening of fibrosis, and improvement of fibrosis with no worsening of NASH will be included as key secondary endpoints.”

Source: [Inventiva NATiV3 design release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-P3-Design-EN-050121-VF.pdf)

<a id="topic-3.1.1.6.1-3"></a>

###### Single histologic endpoints named key primary or key secondary endpoints in the company's financing terms

> “The exercise of the T3 BSAs is subject to the T3 Triggering Event, i.e., release by the Company of topline data announcing that any key primary endpoint or key secondary endpoint of NATiV3 (resolution of NASH without worsening fibrosis and improvement of liver fibrosis without worsening NASH), with any dosage regimen tested in the trial, have been met no later than June 15, 2027.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.6.1-4"></a>

###### Primary outcome measure titled resolution of NASH in the original ClinicalTrials.gov record, April 2021, superseded in October 2021

> “Viewing V1 (2021-04-16)”
> “Resolution of NASH”
> “Resolution of NASH and improvement of fibrosis at Week 72, defined by NASH CRN scores for ballooning of 0 and inflammation of 0 to 1, and fibrosis score ≥1 stage decrease compared to Baseline”
> “[Time Frame: Date of randomisation until the date of biopsy at Week 72]”

Source: [ClinicalTrials.gov NCT04849728 version 1](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=1)

<a id="topic-3.1.1.6.1-5"></a>

###### Composite endpoint carried over from the phase 2b NATIVE trial

> “The primary composite endpoint of part 1 of the NATiV3 Phase III clinical trial is identical to the composite efficacy endpoint used in Inventiva’s NATIVE Phase IIb clinical trial which was met by both lanifibranor doses with statistical significance, including in NASH patients with F2/F3 fibrosis and NASH patients with type 2 diabetes (T2DM).”
> “During the NATIVE Phase IIb trial, 21% and 31% of patients in the lanifibranor 800mg/day and 1200mg/day dose groups respectively achieved the Phase III primary composite endpoint after only 24 weeks of treatment compared to 7% in the placebo arm.”

Source: [Inventiva NATiV3 initiation release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf)

<a id="topic-3.1.1.6.1-6"></a>

###### Phase 2b effect on the composite endpoint by type 2 diabetes status cited for NATiV3

> “The effect size of lanifibranor therapy over placebo in the Phase IIb clinical trial on the composite endpoint”
> “(which corresponds to the primary efficacy endpoint in the NATiV3 Phase III clinical trial), was”
> “higher in patients with T2D than in patients without diabetes: 21% and 26% for lanifibranor 800 and 1200 mg/day, respectively, in patients with T2D compared to 7% and 22%, respectively, in patients without T2D.”

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf)

<a id="topic-3.1.1.6.1-7"></a>

###### FDA draft guidance: histologic endpoints reasonably likely to predict clinical benefit for accelerated approval

> “Because of the slow progression of NASH and the time required to conduct a trial that”
> “recommends sponsors consider the following liver histological improvements as”
> “endpoints reasonably likely to predict clinical benefit to support accelerated approval”
> “Resolution of steatohepatitis on overall histopathological reading and no worsening”
> “Improvement in liver fibrosis greater than or equal to one stage (NASH CRN fibrosis”
> “Both resolution of steatohepatitis and improvement in fibrosis (as defined above).”

Source: [FDA (2018)](https://www.fda.gov/media/119044/download)

<a id="topic-3.1.1.6.1-8"></a>

###### FDA draft guidance: confirmatory outcome trials underway at submission and the composite clinical endpoint

> “For NASH drugs approved on the basis of liver histology under the accelerated approval”
> “pathway, randomized, double-blind, placebo-controlled clinical trials designed to”
> “describe and verify the drug’s clinical benefit should be underway at the time of”
> “submission of the marketing application.  Clinical benefit can be verified by”
> “demonstrating superiority to placebo in delaying disease progression measured by a”

Source: [FDA (2018)](https://www.fda.gov/media/119044/download)

<a id="topic-3.1.1.6.1-9"></a>

###### EMA reflection paper: two composite histologic endpoints required as co-primary endpoints for conditional approval

> “Acceptable intermediate endpoints would consist of two composite endpoints to be evaluated at the”
> “The resolution of NASH – with the presence of any grade of steatosis, and all of the following: No”
> “ballooning, only minimal (grade 1) lobular inflammation and – no worsening of the stage of fibrosis.”
> “The improvement of fibrosis by at least 1 stage without any worsening of NASH (no worsening of”
> “Efficacy for both endpoints should be demonstrated in co-primary fashion, meaning that both will have”
> “to independently demonstrate a statistically significant and clinically relevant difference to placebo.”

Source: [European Medicines Agency NASH reflection paper (2024)](https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-development-medicinal-products-non-alcoholic-steatohepatitis-nash_en.pdf)

<a id="topic-3.1.1.6.1-10"></a>

###### Regulatory consultation before the trial: accelerated and conditional approval on the 72-week histology analysis

> “today announced the details of the Phase III clinical trial with its lead drug candidate lanifibranor in NASH following the end-of-phase II meeting with the U.S. Food and Drug Administration (FDA) and the receipt of the Scientific Advice letter from the European Medicines Agency (EMA).”
> “Inventiva will seek to obtain accelerated approval in the U.S. and conditional approval in the EU for lanifibranor based on a pre-specified histology analysis in approximately 900 patients after 72 weeks establishing a positive benefit-risk ratio.”
> “The duration of 72 weeks was considered adequate by both the FDA and EMA to establish long-term use as well as dose and cumulative drug exposure.”

Source: [Inventiva NATiV3 design release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-P3-Design-EN-050121-VF.pdf)

<a id="topic-3.1.1.6.1-11"></a>

###### Accelerated approval on histologic endpoints and confirmation in a separate outcomes trial after the January 2023 amendments

> “The protocol amendments, submitted to the FDA in January 2023, were designed to align with an FDA public communication suggesting that an alternative approach to seek full approval in patients with MASH could be considered upon submission of positive results of a Phase 3 trial using a histology surrogate endpoint in patients with MASH and a Phase 3 clinical outcome trial in patients with MASH and compensated cirrhosis.”
> “We anticipate submission of an NDA to the FDA for accelerated approval based on liver histological endpoints of approximately 950 patients treated over a 72-week period for our Phase 3 trial, if the data is positive.”
> “We may seek accelerated approval from the FDA and conditional authorization from the European Commission if our NATiV3 Phase 3 clinical trial of lanifibranor in MASH is successful at the 72-week endpoint but, even if granted, accelerated approval and conditional authorization require completion of the trial to obtain full approval.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.6.1-12"></a>

###### Precedent: accelerated approval of resmetirom based on the two single histologic endpoints

> “This indication is approved under accelerated approval based on improvement of MASH and fibrosis [see Clinical Studies (14)].”
> “Efficacy determination was based on the effect of REZDIFFRA on resolution of steatohepatitis without worsening of fibrosis and one stage improvement in fibrosis without worsening of steatohepatitis, on post-baseline liver biopsies collected at 12 months.”
> “Two pathologists, Pathologist A and Pathologist B, independently read the liver biopsies for each patient.”

Source: [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf)

<a id="topic-3.1.1.6.1-13"></a>

###### Reliability of NASH CRN histologic scoring between readers in a phase 2 trial

> “Inter-reader linearly weighted kappas were 0.609, 0.484, 0.328, and 0.517 for steatosis, fibrosis, lobular inflammation, and ballooning, respectively.”
> “Inter-reader unweighted kappas were 0.400 for the diagnosis of NASH, 0.396 for NASH resolution without worsening fibrosis, and 0.366 for fibrosis improvement without worsening NASH.”
> “Simulations show that the lack of reliability of endpoints and inclusion criteria can drastically reduce study power - from >90% in a well-powered study to as low as 40%.”

Source: [Davison et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32610115/)

<a id="topic-3.1.1.6.1-14"></a>

###### EMA reflection paper: observer variability of the NASH CRN system and centralized reading by at least two histopathologists

> “The inter- and intra-observer variability for some of the features of the CRN-system has been revealed”
> “order to limit variability of the methods, use of centralised evaluation by at least two experienced”
> “histopathologists, including algorithms for arbitration is recommended.”

Source: [European Medicines Agency NASH reflection paper (2024)](https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-development-medicinal-products-non-alcoholic-steatohepatitis-nash_en.pdf)

<a id="topic-3.1.1.6.1-15"></a>

###### Digital versus glass slide reading of NATiV3 screening biopsies, AASLD 2025 poster

> “Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 study”
> “Comparison of digital images versus glass slides for the histopathological evaluation of liver biopsy samples according to the NASH-CRN scoring system for MASH: A validation performed as part of the NATiV3 study”
> “C. Lackner, Z. Goodman, D. Tiniakos, P. Hytiroglou, A. Sanyal, S. Francque, P. Huot-”

Source: [Inventiva AASLD 2025 abstracts release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-AASLD-Abstracts-2025-EN-10-07-2025-1.pdf)

<a id="topic-3.1.1.6.1-16"></a>

###### Validation of whole slide images against glass slides for steatohepatitis scoring in clinical trials

> “The results from this validation study support the conclusion that the WSI IMS platform is equivalent to the glass read in reference to a robust glass GT when used by pathologists to evaluate steatohepatitis trial populations for diagnosis and trial‐based scoring criteria and histologic feature scoring during enrollment and for follow‐up timepoints.”

Source: [Pulaski et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11410674/)

<a id="topic-3.1.1.6.1-17"></a>

###### FDA statements on noninvasive biomarkers as replacements for liver biopsy

> “FDA encourages sponsors to identify biochemical or noninvasive imaging biomarkers”
> “that could eventually replace liver biopsies.  Sponsors could use such biomarkers, once”
> “characterized and agreed upon by the FDA, either for patient selection or for assessing”

Source: [FDA (2018)](https://www.fda.gov/media/119044/download)

> “[8/27/2025] FDA's Center for Drug Evaluation and Research, Office of New Drugs has accepted a Letter of Intent for the qualification of Liver Stiffness Measurement by Vibration-Controlled Transient Elastography as a reasonably likely surrogate endpoint for clinical trials in adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver fibrosis (scarring).”
> “This acceptance represents the first step in the Drug Development Tool qualification process, where the company will work with FDA to develop a comprehensive qualification plan for data and validation requirements to support the specific context of use.”

Source: [FDA (2025)](https://www.fda.gov/drugs/drug-alerts-and-statements/fda-accepts-proposal-reasonably-likely-surrogate-endpoint-mash-all-cause-mortality-or-liver-related)

<a id="topic-3.1.1.6.1-18"></a>

###### Noninvasive tests in the exploratory cohort

> “Approximately 200 screen-failed patients from Part 1 of the NATiV3 trial are expected to be included in a new 72-week exploratory cohort aimed at generating results based on non-invasive tests and contributing to the regulatory safety database”

Source: [Inventiva clinical development changes release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Changes-clinical-development-of-lanifibranor-EN-01-04-2023.pdf)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Estimated enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 1000”
> “A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.7.1-2"></a>

###### Enrollment targets and participants randomized in the main and exploratory cohorts, April 2025

> “Inventiva has enrolled 1009 patients in the main cohort and 410 patients in the exploratory cohort exceeding the original target of 969 and 350, respectively.”

Source: [Inventiva NATiV3 enrollment completion release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-End-of-Patient-Randomization-EN-04-01-2025.pdf)

<a id="topic-3.1.1.7.1-3"></a>

###### Statistical power for the sample size calculation and enrollment, company design slide

> “90% considered for sample size calculations”
> “NATiV3 fully recruited with 1009 patients in the main cohort and 410 in the exploratory cohort”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.7.1-4"></a>

###### Participants planned for the histologic analysis supporting the NDA, Form 20-F

> “We anticipate submission of an NDA to the FDA for accelerated approval based on liver histological endpoints of approximately 950 patients treated over a 72-week period for our Phase 3 trial, if the data is positive.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.7.1-5"></a>

###### Enrolled main cohort stated in September 2026

> “NATiV3 enrolled 1,009 adults with biopsy-proven non-cirrhotic MASH and F2/F3 fibrosis, with an additional 410 patients enrolled in an exploratory cohort.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.7.1-6"></a>

###### Estimated enrollment of 2000 in the ClinicalTrials.gov record, April 2021, superseded in March 2023

> “Viewing V1 (2021-04-16)”
> “Enrollment 2000 [Estimated]”
> “A total of 2000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part 1 and Part 2.”

Source: [ClinicalTrials.gov NCT04849728 version 1](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=1)

<a id="topic-3.1.1.7.1-7"></a>

###### Planned histology analysis in about 900 participants, January 2021, superseded in April 2025

> “Seeking of U.S. accelerated approval and EU conditional approval for lanifibranor to be based on 72-week histology analysis in approximately 900 patients”
> “Statistical powering of 90% was considered for the sample size calculations of the Phase III clinical trial.”

Source: [Inventiva NATiV3 design release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-P3-Design-EN-050121-VF.pdf)

<a id="topic-3.1.1.7.1-8"></a>

###### Planned exploratory cohort of about 200 participants, December 2023, superseded in April 2025

> “The trial takes place in 24 countries and in more than 400 clinical sites and to recruit approximately 900 patients to be treated over a 72-week period.”
> “An exploratory cohort is anticipated to enrol approximately 200 patients with NASH and fibrosis screen-failed on histology for the main NATiV3 clinical trial.”

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Analysis periods for the Part B safety analyses in the ClinicalTrials.gov record

> “Using the DBPC on-treatment period, comparing the 2 active arms versus placebo”
> “Using the DBPC +ATE on treatment periods, assessing the 2 active arms. For adverse events, adjudicated liver events, and DILI and MACE events, in addition to the raw cumulative incidence proportions, the exposure-adjusted incidence rates will be provided based on the time patients are at risk.”

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="topic-3.1.1.7.2-2"></a>

###### Histologic analysis population and exploratory cohort contribution to the safety database, Form 20-F

> “We anticipate submission of an NDA to the FDA for accelerated approval based on liver histological endpoints of approximately 950 patients treated over a 72-week period for our Phase 3 trial, if the data is positive.”
> “We anticipate that this exploratory cohort may generate additional results using non-invasive tests and contribute to the safety database requirement to support the planned submission for potential accelerated approval.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Completion of randomization in the main and exploratory cohorts and the drop-out condition, April 2025

> “today announced the completion of patient enrollment in its NATiV3 Phase 3 clinical trial with the randomization of the last patient in the main cohort.”
> “(ii) at the time of completion of enrollment in NATiV3, a drop-out rate of less than 30% before week 72.”

Source: [Inventiva NATiV3 enrollment completion release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-End-of-Patient-Randomization-EN-04-01-2025.pdf)

<a id="topic-3.1.1.8.1-2"></a>

###### Completion of the 72-week treatment period by all participants, September 2026

> “Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohort”
> “With the last patient having completed their final visit, all patients have completed the 72-week treatment period.”

Source: [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.8.1-3"></a>

###### Participants remaining to complete the 72-week biopsy, October 2025

> “Only a few hundred patients remaining to complete their 72-week biopsy”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.8.1-4"></a>

###### Randomized participants, screening, and screen failure rate, December 2023

> “As of December 20, 2023, a total of 793 patients have been randomized in NATiV3 of which 657 in the main cohort and 136 in the exploratory cohort.”
> “are in the screening process and, based on the recent screen failure rate of approximately 80%, Inventiva expects”
> “As of December 20, 2023, 136 patients are randomised in the exploratory cohort including approximately 30% of patients with fibrosis stage F4.”

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf)

<a id="topic-3.1.1.8.1-5"></a>

###### Participants randomized before the voluntary screening pause, February 2024

> “Prior to the voluntary pause, 913 patients were already randomized in the NATiV3 clinical trial including 731 in the main cohort and over 550 patients were in screening.”
> “This is an important milestone as 152 sites of the NATiV3 clinical trial sites are operating under central IRB and have so far randomized over 60% of the patients in the main cohort.”

Source: [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf)

<a id="topic-3.1.1.8.1-6"></a>

###### Treatment duration of participants at the fifth Data Monitoring Committee review, October 2024

> “Among the more than 1000 patients whose data was reviewed, over 800 patients have been treated for more than 24 weeks, the treatment duration evaluated in the Phase 2b, NATIVE, study, and 177 patients have been treated for more than 72 weeks.”

Source: [Inventiva fifth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-5th-DMC-NATiV3-EN-10-30-2024-1.pdf)

<a id="topic-3.1.1.8.1-7"></a>

###### Screen failure rate and enrollment delays stated in the Form 20-F

> “which, together with higher than originally projected screen failure rate resulting in a slower than anticipated enrollment rate, contributed to a delay in patient enrollment.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Demographic and metabolic characteristics of the NATiV3 main cohort compared with NATIVE, company slides

| Characteristic | NATiV3 (main cohort) | NATIVE |
| --- | --- | --- |
| Participants | “NATiV3 N=1009” | “NATIVE N=247” |
| Female | “59%” | “58%” |
| Male | “41%” | “42%” |
| Weight (kg), mean (SD) | “97.10”; “(± 23.6)” | “93.30”; “(± 18.8)” |
| BMI class obese (30 or more) | “75%” | “65%” |
| Type 2 diabetes | “55%” | “42%” |
| HOMA-IR, mean (SD) | “9.8”; “(± 10.2)” | “10.1”; “(± 12.7)” |
| HbA1c, mean (SD) | “6.5%”; “(± 1.0)” | “6.0%”; “(± 0.7)” |
| Adiponectin (µg/mL), mean (SD) | “4.6”; “(± 2.7)” | “5.1”; “(± 2.7)” |

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

> “Baseline characteristics of NATiV3 are aligned with those of Phase 2b NATIVE”
> “median: NATiV3 = 95kg | NATIVE = 92kg”
> “median: NATiV3 = 7.3 | NATIVE = 6.7”
> “median: NATiV3 = 6.2% | NATIVE = 5.9%”
> “median: NATiV3 = 4.0 | NATIVE = 4.5”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.8.2-2"></a>

###### Liver disease characteristics of the NATiV3 main cohort compared with NATIVE, company slides

| Characteristic | NATiV3 (main cohort) | NATIVE |
| --- | --- | --- |
| Fibrosis stage F2 | “33.0%” | “41.3%” |
| Fibrosis stage F3 | “67.0%” | “34.8%” |
| Liver stiffness measurement (kPa), median | “10.1” | “8.9” |
| Controlled attenuation parameter (dB/m), median | “329” | “327” |
| ALT (U/L), median | “50” | “51” |
| AST (U/L), median | “40” | “37” |
| FIB-4 score, median | “1.35” | “1.19” |
| ELF score, median | “9.6” | “9.7” |

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

> “mean ±SD: NATiV3 = 11.1 ± 4.9 | NATIVE = 10.09 ± 5.02”
> “mean ±SD: NATiV3 = 324 ± 48 | NATIVE = 327.7 ± 43.2”
> “mean ±SD: NATiV3 = 59 ± 36 | NATIVE = 62 ± 39”
> “mean ±SD: NATiV3 = 47 ± 26 | NATIVE = 47 ± 32”
> “mean ±SD: NATiV3 = 1.49 ± 0.75 | NATIVE = 1.41 ± 0.87”
> “mean ±SD: NATiV3 = 9.7 ± 0.9 | NATIVE = 9.7 ± 1.0”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.8.2-3"></a>

###### Concomitant SGLT2 inhibitor and GLP-1 receptor agonist use at baseline in the NATiV3 main cohort compared with NATIVE, company slides

| Co-medication at baseline | NATiV3 (main cohort) | NATIVE |
| --- | --- | --- |
| SGLT2 inhibitor, yes | “10.0%” | “2.8%” |
| SGLT2 inhibitor, no | “90.0%” | “97.2%” |
| GLP-1 receptor agonist, yes | “14.0%” | “0.0%” |
| GLP-1 receptor agonist, no | “86.0%” | “0.0%” |

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.1.8.2-4"></a>

###### Interim baseline characteristics of participants randomized in the main cohort, December 2023

> “At baseline, 13% of patients randomized in the main cohort are receiving a stable dose GLP1 receptor agonists and 8% are receiving stable SGLT2 inhibitors.”
> “The main difference in patient characteristics observed thus far is that there is a higher percentage of patients with type 2 diabetes (T2D) in the main cohort of the NATiV3 Phase III trial compared to the NATIVE Phase IIb trial (55% vs 42%, respectively).”

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### Treatment-related suspected unexpected serious adverse reaction of elevated aminotransferases, February 2024

> “This event has been assessed as a treatment-related Suspected Unexpected Serious”
> “The study drug was discontinued for that patient and liver tests which are being closely followed at the clinical site are improving and the patient has been without clinical symptoms throughout the period of observation.”
> “Additional lab tests and a liver biopsy performed after study drug discontinuation provided results compatible with autoimmune hepatitis.”
> “This patient presented at baseline in September 2022 with a histological diagnosis of NASH with stage 2 fibrosis. An earlier diagnostic analysis had raised a suspicion of autoimmune hepatitis dating back to June 2022.”
> “This SUSAR is the first reported in all clinical trials with lanifibranor.”

Source: [Inventiva preliminary full year 2023 results announcement (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-2023-Revenue-et-Cash-EN-02-15-2024-final-1.pdf)

<a id="topic-3.1.1.8.5-2"></a>

###### Other milder aminotransferase elevations among trial participants, Form 20-F

> “Other milder cases of elevation of aminotransferases among trial participants have also been reported.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.1.8.5-3"></a>

###### Recovery of the participant with the suspected unexpected serious adverse reaction, May 2024

> “The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, has been without clinical symptoms throughout the period of observation and has fully recovered.”

Source: [Inventiva fourth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-4th-DMC-NATiV3-EN-05-16-2024.pdf)

<a id="topic-3.1.1.8.5-4"></a>

###### Third Data Monitoring Committee review of blinded safety data, December 2023

> “The DMC review supports the continuation of the NATiV3 clinical trial, in the absence of a  safety signal that would require any modification to the trial protocol.”
> “This safety assessment was based on the review of safety data from more than 500 patients, including patients that have been treated with lanifibranor for more than 72 weeks.”

Source: [Inventiva third NATiV3 DMC release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-3rd-DMC-NATiV3-EN-12-04-2023.pdf)

<a id="topic-3.1.1.8.5-5"></a>

###### Fourth Data Monitoring Committee review of unblinded safety data, May 2024

> “The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.”

Source: [Inventiva fourth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-4th-DMC-NATiV3-EN-05-16-2024.pdf)

<a id="topic-3.1.1.8.5-6"></a>

###### Fifth Data Monitoring Committee review of unblinded safety data, October 2024

> “The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.”
> “The safety data was unblinded to the DMC but remains blinded with respect to the Company.”

Source: [Inventiva fifth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-5th-DMC-NATiV3-EN-10-30-2024-1.pdf)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: results not yet reported and blinded safety information

The ClinicalTrials.gov record gives an actual primary completion date of 2026-09-29 and an estimated study completion date of 2027-09-30. All participants had completed the 72-week treatment period, and Inventiva expected to report topline results in the fourth quarter of 2026. The safety information available comes from company statements on Data Monitoring Committee reviews: one review used safety data from more than 500 participants, including participants treated with lanifibranor for more than 72 weeks; another used unblinded data from more than 900 participants randomized in the main and exploratory cohorts; and at another the data were unblinded to the committee and remained blinded with respect to the company.

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728); [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf); [Inventiva first half 2026 results announcement (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-H1-2026-Financial-Results-EN-09-28-2026.pdf); [Inventiva third NATiV3 DMC release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-3rd-DMC-NATiV3-EN-12-04-2023.pdf); [Inventiva fourth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-4th-DMC-NATiV3-EN-05-16-2024.pdf); [Inventiva fifth NATiV3 DMC release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-5th-DMC-NATiV3-EN-10-30-2024-1.pdf)

<a id="topic-3.1.1.9-2"></a>

###### Summary: histologic surrogate endpoint, endpoint naming, and reader variability

- The primary outcome is histologic: resolution of NASH and improvement of fibrosis at week 72, defined by NASH CRN scores for ballooning of 0, inflammation of 0 to 1, and a fibrosis decrease of at least 1 stage. Inventiva states that accelerated approval and conditional authorization, even if granted, require completion of the trial to obtain full approval.
- The January 2023 protocol amendments replaced the planned Part 2 of NATiV3, a clinical outcome trial in approximately 2,000 participants with F2 and F3 fibrosis for a maximum of seven years, with a separate event-driven phase 3 outcome trial in participants with compensated cirrhosis. The Form 20-F states that the FDA's guidance during a consultation preceding the amendments was to continue NATiV3 as originally planned, and that the FDA did not object to the amendments.
- Sources name the endpoints differently. The ClinicalTrials.gov record names the composite of NASH resolution and fibrosis improvement as the primary outcome, and the investor and analyst day presentation names the composite as the primary endpoint and the two single histologic endpoints as key secondary endpoints. The financing terms in the Form 20-F describe the two single endpoints as “key primary endpoint or key secondary endpoint”. The original registry version (April 2021) titled the primary measure "Resolution of NASH" while defining it as the composite. Efficacy for the accelerated approval of resmetirom was determined on the two single endpoints, and the EMA reflection paper states that efficacy for both endpoints (resolution of NASH and improvement of fibrosis by at least 1 stage) should be demonstrated in co-primary fashion.
- Davison et al. reported inter-reader unweighted kappas of 0.396 for NASH resolution without worsening fibrosis and 0.366 for fibrosis improvement without worsening NASH, and simulations in which unreliable endpoints and inclusion criteria reduced study power from >90% to as low as 40%.

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728); [ClinicalTrials.gov NCT04849728 version 1](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=1); [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Madrigal Pharmaceuticals REZDIFFRA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217785s006lbl.pdf); [European Medicines Agency NASH reflection paper (2024)](https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-development-medicinal-products-non-alcoholic-steatohepatitis-nash_en.pdf); [Davison et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32610115/)

<a id="topic-3.1.1.9-3"></a>

###### Summary: enrollment figures, protocol amendments, and the extension period

- Enrollment figures differ by source and date. The ClinicalTrials.gov record gives an estimated enrollment of 1000 (2000 in the April 2021 version). Inventiva reports 1,009 participants in the main cohort and 410 in the exploratory cohort, exceeding the original targets of 969 and 350. The Form 20-F anticipates an NDA based on histologic endpoints in approximately 950 patients, and the NATiV3 design release planned the histology analysis in approximately 900 patients.
- The January 2023 amendments reduced the number of biopsies per participant from three to two and the trial duration a participant consents to from 7 years to 72 weeks. In 2022, recruitment was put on hold in Ukraine and all planned sites in Russia were removed.
- A treatment-related suspected unexpected serious adverse reaction of elevated aminotransferases, with biopsy results compatible with autoimmune hepatitis, led to a voluntary pause in screening and randomization, an amendment excluding newly screened patients diagnosed with or predisposed to autoimmune liver or thyroid disease, and liver monitoring every 6 weeks. Before the pause, 913 participants had been randomized, including 731 in the main cohort.
- The ClinicalTrials.gov and EU Clinical Trials Information System records describe the 48-week Part B extension as double-blind; the company's last patient visit release describes it as open-label, with all participants, including those originally randomized to placebo, receiving lanifibranor.

Source: [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728); [ClinicalTrials.gov NCT04849728 version 1](https://clinicaltrials.gov/study/NCT04849728?tab=history&a=1); [Inventiva NATiV3 enrollment completion release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-End-of-Patient-Randomization-EN-04-01-2025.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Inventiva NATiV3 design release (2021)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-P3-Design-EN-050121-VF.pdf); [Inventiva clinical development changes release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Changes-clinical-development-of-lanifibranor-EN-01-04-2023.pdf); [Inventiva preliminary full year 2023 results announcement (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Full-Year-2023-Revenue-et-Cash-EN-02-15-2024-final-1.pdf); [Inventiva NATiV3 screening resumption release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATiV3-screening-update-EN-03-07-2024-final.pdf); [EU Clinical Trials Information System 2023-508248-23-00](https://euclinicaltrials.eu/ctis-public/view/2023-508248-23-00); [Inventiva NATiV3 last patient visit release (2026)](https://inventivapharma.com/wp-content/uploads/Inventiva-PR-Inventiva-LVLP-EN-09-02-2026.pdf)

<a id="topic-3.1.1.9-4"></a>

###### Summary: enrolled population and generalizability

- Inventiva reported a recent screen failure rate of approximately 80% in December 2023, and the Form 20-F states that a higher than originally projected screen failure rate slowed enrollment.
- The main cohort differs from the NATIVE population in company slides: type 2 diabetes 55% versus 42%, fibrosis stage F3 67.0% versus 34.8%, obesity 75% versus 65%, GLP-1 receptor agonist use at baseline 14.0% versus 0.0%, and SGLT2 inhibitor use 10.0% versus 2.8%.
- As of December 2023, approximately 70% of participants randomized in the main and exploratory cohorts were from the United States, approximately 20% from Europe, and approximately 10% from Latin America and the rest of the world.
- Exclusion criteria include HbA1c >9% at screening, current insulin treatment, history of heart failure with reduced left ventricular ejection fraction, atrial fibrillation requiring anticoagulation, current approved treatment for NASH or obesity, thiazolidinedione treatment in the prior 12 months, and hemoglobin <11 g/dL in females or <12 g/dL in males.

Source: [Inventiva NATiV3 status update release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-First-patient-randomized-in-China-and-NATiV3-status-update-EN-12-20-2023-2.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm); [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf); [ClinicalTrials.gov NCT04849728](https://clinicaltrials.gov/study/NCT04849728)

<a id="heading-3.1.2"></a>

#### 3.1.2 NATIVE

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov record

> “The purpose of this research is to evaluate the efficacy and the safety of two doses of IVA337 (800mg, 1200 mg) per day for 24 weeks versus placebo in adult NASH patients with liver steatosis and moderate to severe necroinflammation without cirrhosis.”
> “A Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-range, Proof-of-concept, 24-week Treatment Study of IVA337 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.1-2"></a>

###### Study objective in the protocol

> “The study objective is to assess the safety and the efficacy on the activity part of the SAF histological score (inflammation and ballooning) of a 24-week treatment with two doses of lanifibranor (800, 1200 mg/24h) in NASH adult patients.”
> “The goal of the proposed study is to show improvement of cardinal NASH histopathologic features as well as safety data after a 6-month treatment.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.1-3"></a>

###### Objective stated in the design paper

> “NATIVE study (EudraCT: 2016-001979-70, NCT: NCT03008070) aims to assess the safety and the efficacy of a 24-week treatment with lanifibranor (800 and 1200 mg/day) in adult non-cirrhotic NASH patients.”

Source: [Francque et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33038502/)

<a id="topic-3.1.2.1-4"></a>

###### Aim of the trial in the published report

> “Here, we report the results of the NASH Trial to Validate IVA337 Efficacy (NATIVE), a phase 2b, double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of lanifibranor in patients with biopsy-proven, noncirrhotic NASH with severe disease activity.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2017-02-07”
> “Primary Completion (Actual) 2020-02-20”
> “Study Completion (Actual) 2020-03-16”
> “Results First Posted 2021-04-12”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.2-2"></a>

###### Registered locations

> “This study has 85 locations”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.2-3"></a>

###### Countries and screening period in the published report

> “NATIVE was approved by independent ethics committees and the appropriate authorities in 16 countries where at least one patient underwent randomization (Table S1 in the Supplementary Appendix, available with the full text of this article at NEJM.org).”
> “From February 2017 through July 2019, a total of 868 patients underwent screening, and 247 patients were randomly assigned in a 1:1:1 ratio to receive 1200 mg of lanifibranor (83 patients), 800 mg of lanifibranor (83 patients), or placebo (81 patients) orally once daily for 6 months (Fig. S3).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.2-4"></a>

###### Recruitment period in the registry results

> “Recruitment of patients started in February 2017, and last patient was recruited on March 2019. A total of 868 patients were screened for the study.”

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="topic-3.1.2.2-5"></a>

###### Planned sites and study period in the protocol

> “The study will be performed in at least 60 sites across Europe, United States of America (USA) and other countries worldwide (incl. Canada, Australia and Republic of Mauritius).”
> “Studied period: First enrolment: Q1 2017. Expected completion date: 2020.”
> “The total duration of the study is up to 38 months, i.e. at least 30 months of enrollment period and up to 8 months of patient participation.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.2-6"></a>

###### Sponsor and other study identifiers

> “Sponsor Inventiva Pharma”
> “IVA_01_337_HNAS_16_002”
> “2016-001979-70 ( EudraCT Number )”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Phase 2b, randomized, double-blind, placebo-controlled design

> “In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks.”
> “Patients were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of oral lanifibranor or placebo once daily for 24 weeks; randomization was stratified according to diabetic status (absence or presence).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.3-2"></a>

###### Design summary in the design paper

> “NATIVE is a Phase 2b randomised, placebo-controlled, double-blind, parallel-assignment, dose-range study.”
> “This study will evaluate the efficacy of a 24-week treatment of NASH with lanifibranor based on histological evaluations (SAF score) by biopsy.”

Source: [Francque et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33038502/)

<a id="topic-3.1.2.3-3"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Study type | “Interventional” |
| Phase | “Phase 2” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Enrollment | “Enrollment (Actual) 247” |

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.3-4"></a>

###### Treatment groups, blinding, and study duration in the ClinicalTrials.gov record

> “Randomized (stratified on diabetes), placebo-controlled, double-blind, parallel-assignment, dose-range multicenter study”
> “There are 3 parallel treatment groups: placebo, IVA337 800mg once a day (Quaque Die, QD) and IVA337 1200mg QD (identical tablets of 400mg IVA337 or placebo). Both, patient and investigator are blinded.”
> “For each patient, the study duration will be an overall of 6 to 8 months (with a 10-day to 4-week selection period, a 24-week treatment period and a 4-week follow-up period).”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.3-5"></a>

###### Study arms, visit schedule, and selection period in the protocol

> “The study is a three arm (placebo, lanifibranor 800 and 1200 mg/day), randomized (1:1:1), double-blind, placebo-controlled, multicenter, 24-week treatment study.”
> “Patients will undergo 6 visits: screening visit (V-1, -8 weeks to -2 weeks), randomization (V0), interim visit 1 (V1, 4 weeks after V0), interim visit 2 (V2, 10 weeks after V1), End of treatment visit (V3, 10 weeks after V2) and a follow-up visit (4 weeks after V3).”
> “For each patient, the study duration will be an overall of 6 to 8 months (with a 3-day to 4-week selection period, a 24-week treatment period and a 4-week follow-up period).”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.3-6"></a>

###### Randomization procedure in the protocol

> “Patients will be randomized equally 1:1:1 to either dose of lanifibranor or placebo stratified on presence/absence of diabetes.”
> “The randomization list will be setup with blocs of size equal to 6.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.3-7"></a>

###### Screening biopsy and centralized histology reading in the protocol

> “As the main efficacy goal of the study is to assess treatment effect on histologic features of NASH, there will be a centralized reading of slides of a liver biopsy to confirm the diagnosis and assess the severity at screeing phase (V-1) and end of treatment visit (V3).”
> “Patients will be withdrawn from the study at this step in case of TE > 12.5 kPa (i.e. high probability of cirrhosis).”
> “After validation of the histological criteria by the central reading assessment, patients can be randomized.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.3-8"></a>

###### Rationale for the placebo comparator and the 6-month duration in the protocol

> “Placebo is chosen as the comparator, as there is no licensed treatment for NASH.”
> “Therefore, taking into account the postulated end points, a treatment of 6 months in a proof of concept study is sufficient to assess study drug efficacy and will furthermore also limit the time on placebo for one third of the study patients.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.3-9"></a>

###### Trial oversight and sponsor role

> “The sponsor (Inventiva Pharma) designed the trial and monitored the trial sites, collected the data, and analyzed the data.”
> “An earlier version of the manuscript was drafted with the assistance of a medical writer (funded by the sponsor) under the guidance of the authors.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.3-10"></a>

###### Management after the end of treatment in the protocol

> “The trial treatment is stopped after V3.”
> “Safety of withdrawal from treatment groups is assessed during a 30-day assessment phase.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Key eligibility criteria in the published report

> “Patients were eligible for inclusion if they were 18 years of age or older and had noncirrhotic NASH (the diagnosis of which required a Steatosis, Activity, Fibrosis [SAF] grade of 1 or higher for steatosis [range, 0 to 3], hepatocellular ballooning [range, 0 to 2], and lobular inflammation [range, 0 to 2] on liver biopsy); higher grades indicate more-severe disease activity.”
> “The diagnosis was confirmed by a centrally read biopsy sample obtained at screening or in the preceding 6 months (patients whose diagnosis was not confirmed at screening had to have a stable body weight, defined as no more than a 5% loss of initial body weight between the time of biopsy and screening).”
> “Patients with stage F4 fibrosis, classified according to the criteria of both the SAF and NASH Clinical Research Network (NASH CRN) (stages range from F0 [no fibrosis] to F4 [cirrhosis]),10,11 were excluded.”
> “A score of 3 or higher on the SAF-A (the activity part of the SAF scoring system that incorporates the scores for hepatocellular ballooning and lobular inflammation) was also a criterion for eligibility.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.4-2"></a>

###### No fibrosis-stage inclusion criterion other than the exclusion of cirrhosis

> “Eligible adult patients with a confirmed histological diagnosis of NASH should have a SAF Activity score of 3 or 4 (>2) and a SAF Steatosis score ≥ 1. There is no specific criterion related to the fibrosis score except that patients with cirrhosis (F4) were excluded.”

Source: [Francque et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33038502/)

<a id="topic-3.1.2.4-3"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “NASH histological diagnosis according to the currently accepted definition of both EASL and AASLD, requiring the combined presence of steatosis (any degree ≥ 5%) + lobular inflammation of any degree + liver cell ballooning of any amount, on a liver biopsy performed ≤ 6 months before screening in the study or at screening and confirmed by central reading during the screening period and”
> “SAF Activity score of 3 or 4 (>2)”
> “SAF Steatosis score ≥ 1”
> “SAF Fibrosis score < 4”
> “Subject agrees to have a liver biopsy performed after 24 weeks of treatment.”
> “If applicable, have a stable type 2 diabetes, defined as HbA1c ≤ 8.5% and fasting glycemia <10 mmol/L, no changes in medication in the previous 6 months, and no new symptoms associated with decompensated diabetes in the previous 3 months.”
> “Have a stable weight since the liver biopsy was performed defined by no more than a 5 % loss of initial body weight.”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.4-4"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “History of sustained excess alcohol ingestion: daily alcohol consumption > 30 g/day (3 drinks per day) for males and > 20 g/day (2 drinks per day) for females.”
> “Unstable metabolic condition: Weight change > 5kg in the last three months, diabetes with poor glycemic control (HbA1c > 8.5%), introduction of an antidiabetic or of an anti-obesity drug/malabsorptive or restrictive bariatric (weight loss) surgery in the past 6 months prior to screening.”
> “Significant systemic or major illnesses other than liver disease, including congestive heart failure (class C and D of the American Heart Association , AHA), unstable coronary artery disease, cerebrovascular disease, pulmonary disease, renal failure, organ transplantation, serious psychiatric disease, malignancy that, in the opinion of the investigator, would preclude treatment with IVA337 and/or adequate follow up.”
> “Body mass index (BMI) >45 kg/m2.”
> “Type 1 diabetes and type 2 diabetic patient on insulin.”
> “Fasting Triglycerides > 300 mg/dL.”
> “History of, or current cardiac dysrhythmias and/or a history of cardiovascular disease event, including myocardial infarction, except patients with only well controlled hypertension. Any clinically significant ECG abnormality reported by central ECG reading.”
> “Osteopenia or any other well documented Bone disease. Patient without well documented osteopenia treated with vitamin D and/or Calcium based supplements for preventive reasons can be included.”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.4-5"></a>

###### Laboratory criteria for compensated liver disease in the protocol

> “Compensated liver disease with the following hematologic and biochemical criteria before randomization:”
> “ALT < 10xULN”
> “Hemoglobin ≥ 110 g/L (11g/dL) for females and ≥ 120 g/L (12g/dL) for males”
> “Platelets > 100 10^9/L (100 10^3/µL)”
> “Albumin > 36 g/L (3.6 g/dL)”
> “International Normalized Ratio (INR) < 1.4”
> “Serum creatinin < 115 µmol/L (1.3 mg/dL) (men) or < 97 µmol/L (1.1 mg/dL) (women) or estimated glomerular filtration rate ≥ 60 mL/min/1.73m2”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.4-6"></a>

###### Prohibited concomitant medications in the protocol

> “If not specified, the following treatment must be stopped at the latest before randomization.”
> “PPAR Gamma agonists, PPAR Alpha agonists (fibrates), ezetimibe,”
> “Glucagon like peptide-1 receptor agonists (incl. liraglutide, exenatide),”
> “Vitamins E (alpha-tocopherol),”
> “Anticoagulants (incl. warfarin, dabigatran, rivaroxaban, apixaban),”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.4-7"></a>

###### Permitted antidiabetic and lipid-lowering medications in the protocol

> “Treatments are allowed within certain restrictions (described above and below) and provided that they have been kept at stable doses for at least 6 months before the pre-treatment biopsy.”
> “Dipeptidyl peptidase-4 inhibitors,”
> “Sodium-glucose transport protein 2 inhibitors: canagliflozin, dapagliflozin and empagliflozin.”
> “Hyperlipidemia: only statins at stable doses within the past 3 months before pre-study treatment biopsy will be allowed.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Doses, schedule, and duration in the published report

> “Patients were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of oral lanifibranor or placebo once daily for 24 weeks; randomization was stratified according to diabetic status (absence or presence).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.5-2"></a>

###### Arms in the ClinicalTrials.gov record

| Arm | Description |
| --- | --- |
| Experimental: IVA337 1200mg | “IVA337 400mg, once a day (Quaque Die, QD) with food” |
| Experimental: IVA337 800mg | “IVA337 400mg, once a day (Quaque Die, QD) with food” |
| Placebo Comparator: Placebo | “Placebo to match, once a day (Quaque Die, QD) with food” |

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.5-3"></a>

###### Tablets, kits, and administration with breakfast in the protocol

> “Tablets of lanifibranor 400 mg, two doses of lanifibranor (800 and 1200 mg QD), i.e. 3 tablets of 400 mg/placebo per os, during breakfast, once daily (QD) will be evaluated.”
> “Each active tablet contains 400 mg of the active substance lanifibranor in an immediate release formulation.”
> “Placebo Kit: Morning (P+P+P)”
> “800 mg Kit: Morning (P+A+A)”
> “1200 mg Kit: Morning (A+A+A)”
> “Where P denotes the placebo tablet and A denotes the active tablet (400 mg).”
> “They are instructed to take morning 3 tablets with food, i.e. one tablet from each of the containers A, B, and C. The overall treatment duration is 24 weeks.”
> “Dosage modifications are not permitted.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.5-4"></a>

###### Dose selection and food intake rationale in the protocol

> “To improve bioavailability, drug intake is combined with food.”
> “Doses have been selected based on the available biomarker (adiponectin, HDL cholesterol, triglycerides) results in diabetes type 2 patients (Phase IIa study):”
> “The two doses chosen for the trial demonstrated significant improvement in biomarkers of PPAR α, γ and probably δ in diabetic patients.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.5-5"></a>

###### Treatment compliance measures in the protocol

> “remaining tablets will be counted /recorded in the eCRF by sites and monitored by the Clinical Research Associate”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using SAF Activity Score Decrease of at Least 2 Points Without Worsening of Fibrosis as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary end point definition in the published report

> “The primary end point was a decrease of at least 2 points from baseline to week 24 in the SAF-A score and no worsening of fibrosis (i.e., no increase in fibrosis stage based on SAF–NASH CRN criteria).”
> “SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.6.1-2"></a>

###### Primary outcome measure in the ClinicalTrials.gov record

> “SAF Activity Score (SAF-A) Decrease of at Least 2 Points With no Worsening of the CRN Fibrosis Score (CRN-F)”
> “SAF-A is the activity part of the Steatosis Activity Fibrosis [SAF] histological score, calculated as the sum of lobular inflamation score and balloning score.”
> “No worsening of fibrosis means that the CRN fibrosis score (CRN-F) remains stable or decreases.”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.6.1-3"></a>

###### Primary endpoint and responder definition in the protocol

> “Responder is defined as a decrease from baseline to week 24 of at least 2 points of the SAF activity score combining hepatocellular inflammatory and ballooning without worsening of fibrosis. Any stage increase of fibrosis is considered fibrosis progression.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.6.1-4"></a>

###### Primary endpoint in the design paper

> “The primary efficacy endpoint is a 2-point reduction in the activity part of the Steatosis Activity Fibrosis (SAF) histological score (combining inflammation and ballooning) without worsening of fibrosis.”

Source: [Francque et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33038502/)

<a id="topic-3.1.2.6.1-5"></a>

###### Rationale for scoring activity separately from steatosis in the published report

> “Steatosis was assessed separately because it does not reflect liver-cell damage and inflammation per se, outcomes that are included in the SAF concept of “activity” (Fig. S1).”
> “While disease activity should reflect ongoing damage and inflammation, the inclusion of steatosis as part of a composite activity score introduces a risk that these outcomes may be overestimated.”
> “We therefore used the SAF scoring system, which assesses steatosis separately from activity and accounts for necroinflammation without steatosis, in the selection of patients for the trial and to define the primary end point.”
> “The use of the SAF-A score enriched the trial with patients more likely to benefit from pharmacologic treatment. As for the other histologic end points, the validity of the use of the SAF-A score to define the primary end point as a surrogate for long-term outcomes warrants further study.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.6.1-6"></a>

###### Justification for the SAF activity score in the protocol

> “While steatosis is considered to be a relatively benign lesion, ballooning and inflammation define the so-called “activity” of NASH. Activity is very likely driving fibrogenesis, which is the main histological long term prognostic factor for liver-related and also non-liver-related mortality associated with NASH. Reducing activity to prevent fibrogenesis is the treatment goal evaluated in this clinical trial.”
> “The activity sub score of the SAF score has been chosen as the main assessment criteria (63).”
> “By giving an equal weight to both lesion and not including steatosis into this score, a grade of activity > 2 ensures to get at least 95% of NASH (63).”
> “Since this score includes steatosis, which is supposed to be a benign lesion, and underweight ballooning (graded from 0 to 2) compared to steatosis and inflammation (each being graded from 0 to 3), this score does not reflect activity of the disease as accurately as does the activity score of SAF.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.6.1-7"></a>

###### Liver histology as the efficacy measure in FDA and EMA approved phase 3 trials, as stated in the protocol

> “As there is still no non-invasive tool sufficiently validated to accurately assess both the diagnosis as well as the treatment response in NASH, the only reliable tool to assess treatment efficacy is liver histology.”
> “Also in the current Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved Phase III trials, treatment efficacy is defined based on histological criteria and consequently liver biopsy is a prerequisite to accurately evaluate both the baseline liver status of the patient as well as the efficacy of the treatment after a predefined treatment period.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.6.1-8"></a>

###### Regulatory context for histologic surrogate end points in the published report

> “Resolution of NASH and regression of fibrosis are currently considered to be likely surrogate outcomes for the prevention of progression to cirrhosis and associated complications.”
> “When the analysis was restricted to patients with significant (stage F2) or advanced (stage F3) fibrosis (i.e., those who compose the target population for the treatment of noncirrhotic NASH according to regulatory guidance), similar results were obtained, a finding that supports the potential for benefits with lanifibranor as compared with placebo.”
> “Regression of fibrosis in NASH is associated with decreased risk of liver-related events19 and is a surrogate end point for regulatory approval.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.6.1-9"></a>

###### Secondary histologic and nonhistologic end points in the published report

> “Secondary histologic end points included resolution of NASH (defined as a ballooning grade of 0 and a lobular inflammation grade of ≤1) and no worsening of fibrosis; improvement in fibrosis stage of at least 1 and no worsening of NASH (i.e., no worsening in either steatosis, ballooning, or lobular inflammation); Nonalcoholic Fatty Liver Disease Activity Score (NAS) improvement (defined as a decrease of ≥2 points from baseline to week 24 in the NAS, which is the sum of the scores for steatosis [range, 0 to 3], ballooning [range, 0 to 2], and lobular inflammation [range, 0 to 3], with higher scores indicating greater disease activity) and no worsening of fibrosis12; resolution of NASH and an improvement in fibrosis stage of at least 1 (a composite end point); change in scores for the components of the SAF and NASH CRN scoring system (steatosis, activity, inflammation, ballooning, and fibrosis); and change in the modified Ishak score.”
> “Nonhistologic secondary end points included changes in liver enzyme levels (alanine aminotransferase, aspartate aminotransferase, and γ-glutamyltransferase); changes in measures of glucose metabolism (fasting levels of glucose, insulin, and glycated hemoglobin and homeostatic model assessment of insulin resistance [HOMA-IR] index score); changes in lipid levels (total cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, triglycerides, and apolipoprotein A1); change in adiponectin level; and changes in inflammatory markers (fibrinogen, high-sensitivity C-reactive protein, α2-macroglobulin, and haptoglobin).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.6.1-10"></a>

###### Exploratory end points, including quality of life, in the published report

> “Exploratory end points included change in the apoptosis marker cytokeratin 18 M30; changes in serum markers of fibrosis and collagen turnover (ratio of tissue inhibitor of metalloproteinase 1 to matrix metalloproteinase 2, N-terminal type III collagen propeptide [Pro-C3] level, and scores on the Enhanced Liver Fibrosis test and Fibrosis-4 index); changes in other lipid levels (apolipoprotein B and C3); changes on transient elastography (FibroScan, Echosens) with controlled attenuation parameter; and change in quality of life.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.6.1-11"></a>

###### Quality-of-life questionnaires assessed in the protocol

> “QOL questionnaires including the Flinders Fatigue scale (FFS) and the SF-36v2 health survey”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.6.1-12"></a>

###### Registered secondary end point definitions for NASH resolution and fibrosis improvement

> “Resolution of NASH is defined as a CRN Inflammation score equal to 0 or 1, and a CRN Ballooning score equal to 0. No worsening of fibrosis means that the CRN fibrosis score remains stable or decreases.”
> “Improvement of fibrosis is defined as a decrease of at least one stage in CRN Fibrosis score. No worsening of NASH is defined as no increase of CRN Steatosis score, no increase of CRN Inflammation score ans no increase of CRN Ballooning score.”
> “NASH improvement is defined as a decrease of at least 2 points in NAS score (sum of CRN Steatosis, Inflammation and Ballooning scores) without worsening of CRN Fibrosis score.”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.6.1-13"></a>

###### Histology reading by one blinded pathologist

> “All biopsy samples were read serially by one pathologist who was unaware of the time at which the samples were obtained (baseline or end of assigned regimen), the trial-group assignment, and the identity of the person who assessed the adequacy of the samples.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.6.1-14"></a>

###### Protocol version 5.0, July 2019: secondary endpoints updated

> “Version 5.0 July 09th, 2019 Updating the secondary endpoints, safety and biomarkers analysis performed”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned sample size and power in the protocol

> “At least 300 patients will be screened, to randomize 225 patients (75 patients/arm).”
> “The expected rate of responders according to the retained definition was estimated to 10% for the placebo by a group of clinical expert. An excess rate of responders of 20% was accepted as clinically pertinent.”
> “The sample size required to reach a power of at least 80% is 72 patients per group with a two-sided alpha of 0.025 (adjustment for multiplicity).”
> “The sample size is therefore rounded in the conservative side of 75 patients per group.”
> “In case the end of study liver biopsy slides are not available or not interpretable in more than 5% of patients, an amendment will be submitted to increase sample size accordingly.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.7.1-2"></a>

###### Randomized participants and per-protocol population in the published report

> “From February 2017 through July 2019, a total of 868 patients underwent screening, and 247 patients were randomly assigned in a 1:1:1 ratio to receive 1200 mg of lanifibranor (83 patients), 800 mg of lanifibranor (83 patients), or placebo (81 patients) orally once daily for 6 months (Fig. S3).”
> “All patients who had undergone randomization received at least one dose of the assigned regimen, and no patient was excluded from the full analysis population.”
> “Major protocol deviations occurred in 53 patients (34 did not have biopsy data available at the end of the treatment period and 19 had other major protocol deviations), who were not included in the per-protocol population, which comprised 194 patients (Table S3).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.7.1-3"></a>

###### Missing week 24 biopsies by group in the full analysis population

> “Missing data for the 34 patients in the full analysis population (11 in the 800-mg lanifibranor group, 9 in the 1200-mg lanifibranor group, and 14 in the placebo group had missing biopsy samples at week 24) were handled with multiple imputation (details are provided in the Supplementary Appendix).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.7.1-4"></a>

###### Enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 247”

Source: [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070)

<a id="topic-3.1.2.7.1-5"></a>

###### Participants analyzed at baseline in the registry results

> “Overall Number of Baseline Participants 83 83 81 247”

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Full analysis, safety, and per-protocol populations in the published report

> “The full analysis population included all patients who underwent randomization and received at least one dose of the assigned regimen and was identical to the safety analysis population.”
> “The per-protocol population included all patients who had biopsy data available at the end of the treatment period and no major protocol deviations.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.7.2-2"></a>

###### Analysis sets defined in the protocol

> “The full analysis set consists of all randomized patients who received at least one dose of the assigned treatment.”
> “The randomized set of patients consists of all randomized patients.”
> “This set is composed of all patients free from major protocol deviation which can bias the estimate of the treatment effect.”
> “The safety set of patients consists of the FAS who will have taken at least one dose of treatment and who have at least one post-baseline assessment of safety, regardless any protocol deviations.”
> “The primary population will be the intent to treat FAS population composed of all randomized subject who received at least one dose.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.7.2-3"></a>

###### Primary analysis method and missing-data rule in the protocol

> “The primary tests of hypotheses will be the Cochran Mantel Haenszel test stratified on diabetes comparing the high dose to placebo and the low dose to placebo.”
> “The primary rule for handling the missing data is to consider non-responders all patients who are not confirmed responders.”
> “There is no planned interim analysis for success.”

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf)

<a id="topic-3.1.2.7.2-4"></a>

###### Multiplicity adjustment, multiple imputation, and sensitivity analyses in the published report

> “For statistical tests, the type I error risk was set at 5% (two-sided) in accordance with the protocol. Adjustments for multiplicity testing in the primary analysis were performed with the use of the Hochberg procedure; each active-treatment group was compared with the placebo group. No multiplicity adjustments for the secondary and exploratory end points were defined.”
> “Comparisons of histologic responses among the trial groups were performed with the use of the Cochran–Mantel–Haenszel test stratified according to diabetic status at baseline.”
> “The primary analyses that we report here were performed in the full analysis population with the use of multiple imputation for missing data, including missing or inadequate biopsy data at the end of the treatment period (see the Supplementary Appendix). We also report the analyses that were performed with the use of single imputation to treat missing data as nonresponses, as specified in the statistical analysis plan.”
> “In addition, sensitivity analyses were conducted on the basis of complete cases (i.e., those with biopsy samples available at both baseline and the end of assigned regimen), as specified in the statistical analysis plan. Other analyses were performed in the per-protocol population and in the subgroups defined according to significant (moderate) or advanced fibrosis and diabetic status.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.7.2-5"></a>

###### Analysis of continuous secondary end points in the published report

> “Comparisons of quantitative secondary end points among the trial groups were assessed with the use of mixed models for repeated measures, with the absolute change in the value of the continuous variable from baseline as the end point; the time, trial group, diabetic status, trial-group–by–time interaction, and baseline value of the variable as fixed effects; a time-repeated effect within each subject; and an unstructured variance–covariance matrix.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Screening, randomization, and completion in the published report

> “From February 2017 through July 2019, a total of 868 patients underwent screening, and 247 patients were randomly assigned in a 1:1:1 ratio to receive 1200 mg of lanifibranor (83 patients), 800 mg of lanifibranor (83 patients), or placebo (81 patients) orally once daily for 6 months (Fig. S3).”
> “Among the 247 patients in the full analysis population, 228 completed the trial (77 patients in each lanifibranor group and 74 in the placebo group).”
> “Major protocol deviations occurred in 53 patients (34 did not have biopsy data available at the end of the treatment period and 19 had other major protocol deviations), who were not included in the per-protocol population, which comprised 194 patients (Table S3).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.1-2"></a>

###### Screen failures in the registry results

> “A total of 247 patients were randomised, and 621 were not randomised.Main reason for non randomization was inclusion/exclusion criteria not met (470 - 76%).”

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="topic-3.1.2.8.1-3"></a>

###### Participant flow and reasons for not completing in the registry results

| Milestone or reason | Lanifibranor 1200mg | Lanifibranor 800mg | Placebo |
| --- | --- | --- | --- |
| Started | “83” | “83” | “81” |
| Completed | “77” | “77” | “74” |
| Not completed | “6” | “6” | “7” |
| Adverse event | “3” | “3” | “3” |
| Lost to follow-up | “1” | “1” | “0” |
| Non compliance | “0” | “1” | “1” |
| Use of prohibited drug | “0” | “0” | “2” |
| Withdrawal by patient and adverse event non fatal | “0” | “1” | “0” |
| Withdrawal by subject | “2” | “0” | “1” |

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Baseline characteristics summarized in the published report

> “The mean age of the patients was 54 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 33; 144 (58%) were female, 232 (94%) were White, and 103 (42%) had type 2 diabetes mellitus.”
> “Significant or advanced fibrosis (stages F2 and F3, respectively) was present in 188 patients (76%), and most patients had highly active NASH (the mean [±SD] SAF-A score was 3.3±0.5, and 73% had an NAS of ≥6, which indicates high disease activity). The median duration between screening biopsy and randomization was 2.3 months (range, 0.5 to 9.2).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.2-2"></a>

###### Demographic and clinical characteristics at baseline, full analysis population

| Characteristic | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) | Overall (N=247) |
| --- | --- | --- | --- | --- |
| Female sex, no. (%) | “49 (59)” | “54 (65)” | “41 (51)” | “144 (58)” |
| Age, yr | “52.2±13.8” | “55.0±10.4” | “53.4±13.1” | “53.6±12.5” |
| White race, no. (%) | “78 (94)” | “80 (96)” | “74 (91)” | “232 (94)” |
| Weight, kg | “93.0±19.9” | “91.6±19.3” | “95.1±17.3” | “93.2±18.9” |
| Body-mass index | “33.3±5.5” | “32.5±5.5” | “32.8±5.1” | “32.9±5.4” |
| Type 2 diabetes mellitus, no. (%) | “35 (42)” | “33 (40)” | “35 (43)” | “103 (42)” |
| Median time between screening biopsy and randomization (range), mo | “2.4 (0.5–7.0)” | “2.6 (0.5–9.2)” | “2.0 (0.5–7.4)” | “2.3 (0.5–9.2)” |
| Steatosis grade | “2.6±0.6” | “2.6±0.7” | “2.5±0.7” | “2.5±0.7” |
| Lobular inflammation grade | “1.5±0.5” | “1.5±0.5” | “1.5±0.5” | “1.5±0.5” |
| Ballooning grade | “1.8±0.4” | “1.7±0.4” | “1.8±0.4” | “1.8±0.4” |
| Fibrosis stage | “2.1±0.8” | “2.1±0.8” | “2.0±0.9” | “2.1±0.8” |
| Fibrosis stage F2 or F3, no. (%) | “63 (76)” | “68 (82)” | “57 (70)” | “188 (76)” |
| SAF-A score | “3.3±0.5” | “3.2±0.5” | “3.3±0.5” | “3.3±0.5” |
| NAS | “5.9±0.9” | “5.9±1.0” | “5.9±1.1” | “5.9±1.0” |
| NAS ≥6, no. (%) | “61 (73)” | “63 (76)” | “56 (69)” | “180 (73)” |
| Alanine aminotransferase, IU/liter | “63.6±43.4” | “64.1±41.4” | “56.9±31.6” | “61.6±39.2” |
| Aspartate aminotransferase, IU/liter | “43.9±24.8” | “53.9±43.4” | “43.3±24.1” | “47.1±32.3” |
| γ-Glutamyltransferase, IU/liter | “67.1±93.1” | “101.6±146.1” | “67.9±80.4” | “78.9±111.2” |
| Fasting HDL cholesterol, mmol/liter | “1.2±0.3” | “1.3±0.3” | “1.2±0.3” | “1.2±0.3” |
| Fasting triglycerides, mmol/liter | “2.0±0.9” | “1.9±0.9” | “2.0±0.8” | “2.0±0.9” |
| Fasting glucose, mmol/liter | “5.9±1.1” | “6.2±1.8” | “6.0±1.6” | “6.0±1.5” |
| Glycated hemoglobin, % | “6.1±0.7” | “6.1±0.8” | “6.0±0.7” | “6.0±0.7” |
| Fasting insulin, pmol/liter | “274.7±321.2” | “231.9±191.9” | “234.0±254.6” | “246.9±260.7” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.2-3"></a>

###### Baseline characteristics of participants with type 2 diabetes

> “A total of 103 patients who underwent randomization had type 2 diabetes mellitus; the mean age of these patients was 56 years, the mean body-mass index was 33, 62 (60%) were women, 83 (81%) had significant or advanced fibrosis, and 84 (82%) had an NAS of 6 or greater.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.2-4"></a>

###### Selection of more severe disease through the SAF-A criterion

> “The use of the SAF-A score leads to a selection of patients with more-severe disease activity and fibrosis,35 as was observed in the current trial, in which 76% of patients had significant or advanced fibrosis, despite the fact that no inclusion criterion with respect to fibrosis stage was set (except for the exclusion of patients with cirrhosis).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.2-5"></a>

###### Antidiabetic medication, prediabetes, obesity, and statin use in the enrolled population

> “Of 247 patients enrolled, 228 completed the study; mean age was 54 years, 58% were female, 94% were Caucasian, mean body mass index (BMI) was 33 kg/m2; 42% (n = 103) had T2D. Of these, 83% received metformin (alone or in combination anti-diabetic treatment), 22%, sulphonylurea; 11%, dipeptidyl peptidase-4 inhibitor; 7% sodium-glucose cotransporter-2 inhibitor medication; 13% had no antidiabetic treatment.”
> “Among 144 patients without T2D, 47 (33%) had prediabetes.”
> “Overall, 20% of patients took statins (22%, 22%, 16% with lanifibranor 1200 mg, 800 mg, and placebo respectively).”
> “Of 247 patients enrolled, 161 (65%) patients were obese (BMI ≥ 30) and 86 (35%) patients had a BMI < 30 at baseline (Supplementary Table 1).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.2-6"></a>

###### Age categories and race in the registry results

| Characteristic | IVA337 1200mg | IVA337 800mg | Placebo | Total |
| --- | --- | --- | --- | --- |
| Age between 18 and 65 years | “67” | “69” | “63” | “199” |
| Age 65 years or older | “16” | “14” | “18” | “48” |
| American Indian or Alaska Native | “0” | “0” | “2” | “2” |
| Asian | “2” | “1” | “2” | “5” |
| Native Hawaiian or Other Pacific Islander | “0” | “1” | “0” | “1” |
| Black or African American | “3” | “1” | “3” | “7” |
| White | “78” | “80” | “74” | “232” |

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="topic-3.1.2.8.2-7"></a>

###### Region of enrollment in the registry results

| Country | IVA337 1200mg | IVA337 800mg | Placebo | Total |
| --- | --- | --- | --- | --- |
| Bulgaria | “17” | “16” | “22” | “55” |
| France | “15” | “15” | “9” | “39” |
| United States | “13” | “11” | “12” | “36” |
| Belgium | “10” | “11” | “11” | “32” |
| Australia | “3” | “7” | “3” | “13” |
| Germany | “7” | “3” | “3” | “13” |
| Spain | “3” | “4” | “5” | “12” |
| Czechia | “3” | “2” | “3” | “8” |
| Canada | “3” | “1” | “4” | “8” |
| United Kingdom | “3” | “2” | “2” | “7” |
| Mauritius | “2” | “3” | “2” | “7” |
| Poland | “1” | “2” | “3” | “6” |
| Italy | “3” | “1” | “1” | “5” |
| Switzerland | “0” | “3” | “1” | “4” |
| Austria | “0” | “1” | “0” | “1” |
| Slovenia | “0” | “1” | “0” | “1” |

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Primary endpoint: full analysis population with multiple imputation

> “In the full analysis population in which missing data were handled with multiple imputation, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis (the primary end point) was significantly higher among those who received the 1200-mg dose (55%), but not among those who received the 800-mg dose (48%), of lanifibranor than among those who received placebo (33%) (risk ratio for a response in the 1200-mg lanifibranor group vs. the placebo group, 1.7; 95% confidence interval [CI], 1.2 to 2.3; P=0.007; risk ratio in the 800-mg lanifibranor group vs. the placebo group, 1.5; 95% CI, 1.0 to 2.1; P=0.07) (Figure 1).”
> “In the analysis of the primary end point, an ascending Hochberg procedure was used to adjust for multiplicity testing (each dose of lanifibranor was compared with placebo).”
> “Missing data for the 34 patients in the full analysis population (11 in the 800-mg lanifibranor group, 9 in the 1200-mg lanifibranor group, and 14 in the placebo group had missing biopsy samples at week 24) were handled with multiple imputation (details are provided in the Supplementary Appendix).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-2"></a>

###### Primary endpoint: nonresponder imputation, complete-case, per-protocol, and F2 or F3 fibrosis analyses

> “Results were similar in the prespecified analyses in which missing data were imputed as nonresponses and in the complete-case analyses (Fig. S9 and Tables S4 and S5). The results were also similar in the per-protocol population and among 188 patients with significant or advanced fibrosis.”
> “Significant or advanced fibrosis (stages F2 and F3, respectively) was present in 188 patients (76%)”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-3"></a>

###### Key secondary histologic endpoints: multiple imputation

> “Analyses were performed with multiple imputation of missing data.”
> “Resolution of NASH without worsening of fibrosis at week 24 from baseline was observed in 49% of patients who received the 1200-mg dose of lanifibranor, in 39% of patients who received the 800-mg dose, and in 22% of patients who received placebo (risk ratio for a response in the 1200-mg lanifibranor group vs. the placebo group, 2.2; 95% CI, 1.5 to 3.3; and risk ratio in the 800-mg lanifibranor group vs. the placebo group, 1.7; 95% CI, 1.1 to 2.7) (Figure 1 and Table S5).”
> “Improvement in fibrosis stage of at least 1 without worsening of NASH was observed in 48% of patients in the 1200-mg lanifibranor group, in 34% of patients in the 800-mg lanifibranor group, and in 29% of patients in the placebo group (risk ratio in the 1200-mg lanifibranor group vs. the placebo group, 1.7; 95% CI, 1.2 to 2.5; and risk ratio in the 800-mg lanifibranor group vs. the placebo group, 1.2; 95% CI, 0.7 to 1.9) (Figure 1).”
> “Resolution of NASH and improvement in fibrosis stage of at least 1 (composite end point) was observed in 35% of patients in the 1200-mg lanifibranor group, in 25% of patients in the 800-mg lanifibranor group, and in 9% of patients in the placebo group (risk ratio in the 1200-mg lanifibranor group vs. the placebo group, 4.0; 95% CI, 2.0 to 7.7; and risk ratio in the 800-mg lanifibranor group vs. the placebo group, 2.6; 95% CI, 1.2 to 5.5) (Figure 1).”
> “In this trial, a dose-dependent improvement in SAF-A score and its individual components was noted with lanifibranor.”
> “In this trial, other findings from the secondary end-point analyses suggest that the 1200-mg dose of lanifibranor may have led to a regression of fibrosis.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-4"></a>

###### Histologic endpoints in participants with F2 or F3 fibrosis: journal report

> “Among patients with significant or advanced fibrosis, the results were also better in the lanifibranor groups than in the placebo group.”
> “When the analysis was restricted to patients with significant (stage F2) or advanced (stage F3) fibrosis (i.e., those who compose the target population for the treatment of noncirrhotic NASH according to regulatory guidance), similar results were obtained, a finding that supports the potential for benefits with lanifibranor as compared with placebo.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-5"></a>

###### Primary and key secondary histologic endpoints: ITT and per-protocol populations, company topline release

> “ITT: includes all patients randomized in the trial.”
> “PP: includes all patients with paired biopsies and without deviation impacting efficacy assessment.”
> “Statistically significant in accordance to the statistical analysis plan (SAP)”

Source: [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf)

| Endpoint at week 24 | ITT placebo | ITT lanifibranor 800 mg | ITT lanifibranor 1200 mg | PP placebo | PP lanifibranor 800 mg | PP lanifibranor 1200 mg |
| --- | --- | --- | --- | --- | --- | --- |
| Number of participants | “(N = 81)” | “(N = 83)” | “(N = 83)” | “(N = 62)” | “(N = 63)” | “(N = 69)” |
| Decrease of at least 2 points in SAF activity score (primary) | “27%” | “41% P=0.061” | “49% P=0.004*” | “34%” | “51% P=0.058” | “55% P=0.015*” |
| Resolution of NASH and no worsening of fibrosis | “19%” | “33% P=0.043*” | “45% P<0.001*” | “23%” | “40% P=0.039*” | “49% P=0.002*” |
| Improvement of fibrosis by at least one stage and no worsening of NASH | “24%” | “28% P=0.53” | “42% P=0.011*” | “29%” | “32% P=0.75” | “46% P=0.04*” |
| Resolution of NASH and improvement of fibrosis | “7%” | “21% P=0.017*” | “31% P<0.001*” | “10%” | “24% P=0.036*” | “33% P=0.001*” |
| Decrease of at least 2 points in NAS and no worsening of fibrosis | “32%” | “52% P=0.01*” | “64% P<0.001*” | “40%” | “62% P=0.02*” | “71% P<0.001*” |

Source: [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf)

<a id="topic-3.1.2.8.3-6"></a>

###### Resolution of NASH without worsening of fibrosis in participants with F2 or F3 fibrosis: ITT and per-protocol populations, company topline release

> “Resolution of NASH and no worsening of fibrosis(2) in F2/F3 patients(3)”
> “Includes 188 patients in the ITT population and 149 in the Per Protocol population.”

Source: [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf)

| Population | Placebo | Lanifibranor 800 mg | Lanifibranor 1200 mg |
| --- | --- | --- | --- |
| ITT, F2 or F3 fibrosis | “9%” | “34% P=0.011*” | “44% P<0.001*” |
| Per protocol, F2 or F3 fibrosis | “11%” | “40% P=0.016*” | “51% P<0.001*” |

Source: [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf)

<a id="topic-3.1.2.8.3-7"></a>

###### Histologic endpoints: participants with a response, missing data counted as nonresponse, registry results

> “Patients with missing data are considered as non-responders.”
> “Responders rates were compared between the placebo and lanifibranor 1200 mg at the end of the treatment period (week 24) using a Cochran Mantel Haenzel test stratified on diabetic status at baseline (that was the stratified factors in the randomisation).”

Source: [ClinicalTrials.gov NCT03008070 API record](https://clinicaltrials.gov/api/v2/studies/NCT03008070)

| Outcome measure at 24 weeks (participants with a response) | IVA337 1200mg | IVA337 800mg | Placebo |
| --- | --- | --- | --- |
| Overall number of participants analyzed | “83” | “83” | “81” |
| SAF-A decrease of at least 2 points with no worsening of CRN-F (primary) | “41” | “34” | “22” |
| NASH improvement (NAS decrease of at least 2 points without worsening of fibrosis) | “53” | “43” | “26” |
| NASH resolution and no worsening of fibrosis | “37” | “27” | “15” |
| Improvement of fibrosis by at least 1 stage and no worsening of NASH | “35” | “23” | “19” |
| Resolution of NASH and improvement of fibrosis by at least 1 stage | “26” | “17” | “6” |
| Activity (SAF-A) improvement | “62” | “54” | “40” |
| Steatosis (CRN-S) improvement | “54” | “46” | “21” |
| Lobular inflammation (CRN-I) improvement | “43” | “34” | “30” |
| Hepatocyte ballooning (CRN-B) improvement | “60” | “54” | “37” |
| Fibrosis (CRN-F) improvement | “36” | “28” | “22” |
| Modified Ishak fibrosis (ISHAK-F) improvement | “41” | “32” | “25” |

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="topic-3.1.2.8.3-8"></a>

###### Liver enzymes: adjusted mean change at week 24, completers in the full analysis population

> “Liver enzyme levels decreased and the levels of the majority of lipid, inflammatory, and fibrosis biomarkers improved in the lanifibranor groups.”
> “The adjusted mean decrease in alanine aminotransferase level was 25 U per liter in the 1200-mg lanifibranor group, 26 U per liter in the 800-mg lanifibranor group, and 1 U per liter in the placebo group (Table 2). The decreases in the aspartate aminotransferase and γ-glutamyltransferase levels were in a similar direction, with greater decreases in the lanifibranor groups than in the placebo group.”
> “Laboratory Measures at Week 24 among the Patients in the Full Analysis Population Who Completed the Trial.”
> “A total of 228 patients completed their week-24 visit.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
| --- | --- | --- | --- |
| Alanine aminotransferase, U/liter | “−24.54 (−32.06 to −17.01)” | “−26.08 (−33.67 to −18.50)” | “−1.40 (−9.04 to 6.25)” |
| Aspartate aminotransferase, U/liter | “−12.04 (−18.29 to −5.79)” | “−15.11 (−21.43 to −8.80)” | “−0.08 (−6.43 to 6.26)” |
| γ-Glutamyltransferase, U/liter | “−27.87 (−38.88 to −16.86)” | “−43.38 (−54.46 to −32.29)” | “4.41 (−6.76 to 15.58)” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-9"></a>

###### Lipids and apolipoproteins: adjusted mean change at week 24, completers in the full analysis population

> “Laboratory Measures at Week 24 among the Patients in the Full Analysis Population Who Completed the Trial.”
> “Also, the patients who received lanifibranor had an increase in HDL cholesterol level and a decrease in serum triglyceride level, two major cardiovascular risk factors.”
> “Adjusted mean absolute changes and 95% confidence intervals were derived with the use of mixed models for repeated measures”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
| --- | --- | --- | --- |
| Total cholesterol, mmol/liter | “−0.07 (−0.22 to 0.07)” | “−0.02 (−0.17 to 0.13)” | “0.01 (−0.14 to 0.16)” |
| Fasting HDL cholesterol, mmol/liter | “0.11 (0.06 to 0.15)” | “0.16 (0.12 to 0.21)” | “0.01 (−0.04 to 0.05)” |
| Fasting LDL cholesterol, mmol/liter | “0.03 (−0.11 to 0.16)” | “0.03 (−0.11 to 0.16)” | “0.01 (−0.12 to 0.15)” |
| Fasting triglycerides, mmol/liter | “−0.44 (−0.61 to −0.27)” | “−0.49 (−0.66 to −0.31)” | “0.06 (−0.12 to 0.23)” |
| Fasting apolipoprotein A1, mg/dl | “−4.39 (−8.64 to −0.13)” | “−0.29 (−4.61 to 4.04)” | “0.03 (−4.27 to 4.33)” |
| Fasting apolipoprotein B, mg/dl (exploratory) | “−11.61 (−15.64 to −7.57)” | “−11.51 (−15.61 to −7.41)” | “−1.85 (−5.79 to 2.09)” |
| Fasting apolipoprotein C3, μg/dl (exploratory) | “−9.98 (−17.74 to −2.22)” | “−8.08 (−16.02 to −0.13)” | “10.31 (2.67 to 17.94)” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-10"></a>

###### Glycemic markers and insulin resistance: adjusted mean change at week 24, completers in the full analysis population

> “The adjusted mean change in glycated hemoglobin level was −0.4% in the 1200-mg lanifibranor group, −0.4% in the 800-mg lanifibranor group, and 0.1% in the placebo group.”
> “Laboratory Measures at Week 24 among the Patients in the Full Analysis Population Who Completed the Trial.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
| --- | --- | --- | --- |
| Fasting glucose, mmol/liter | “−0.60 (−0.83 to −0.37)” | “−0.78 (−1.01 to −0.55)” | “0.24 (0.01 to 0.47)” |
| Glycated hemoglobin, % | “−0.41 (−0.51 to −0.32)” | “−0.38 (−0.47 to −0.28)” | “0.07 (−0.02 to 0.17)” |
| Fasting insulin, pmol/liter | “−114.91 (−138.09 to −91.73)” | “−118.66 (−141.66 to −95.67)” | “−35.7 (−58.59 to −12.82)” |
| Fasting HOMA-IR index score | “−5.46 (−6.60 to −4.32)” | “−5.79 (−6.92 to −4.65)” | “−1.47 (−2.59 to −0.35)” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-11"></a>

###### Glycemic markers in participants with type 2 diabetes: journal report

> “A total of 103 patients who underwent randomization had type 2 diabetes mellitus; the mean age of these patients was 56 years, the mean body-mass index was 33, 62 (60%) were women, 83 (81%) had significant or advanced fibrosis, and 84 (82%) had an NAS of 6 or greater.”
> “The patients with diabetes had improvements in histologic features of NASH that were similar to those in the full analysis population, and they had more pronounced reductions in fasting levels of glucose, insulin, and glycated hemoglobin than those observed in the full analysis population.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-12"></a>

###### Glycemic markers and adiponectin by diabetes status: mean absolute change at week 24, congress poster

> “Table 1. Metabolic Response By Diabetes Status (NATIVE, Week 24)”
> “Mean absolute change from baseline; adiponectin shown as fold-increase.”
> “N=247 (103 T2DM / 144 non-T2DM)”
> “Glucose, HbA1c and insulin resistance improve in patients with AND without T2DM.”

Source: [Holleboom et al. (2026)](https://inventivapharma.com/wp-content/uploads/Metabolic-Benefits-of-Lanifibranor-in-Patients-With-and-Without-Type-2-Diabetes_ParisMASH_poster.pdf)

| Parameter | T2DM, lanifibranor 800 mg | T2DM, lanifibranor 1200 mg | T2DM, placebo | No T2DM, lanifibranor 800 mg | No T2DM, lanifibranor 1200 mg | No T2DM, placebo |
| --- | --- | --- | --- | --- | --- | --- |
| Fasting plasma glucose, mmol/L | “−1.71” | “−0.88” | “+0.29” | “−0.49” | “−0.39” | “+0.16” |
| HbA1c, % | “−0.60” | “−0.72” | “+0.10” | “−0.21” | “−0.25” | “+0.08” |
| HOMA index | “−10.62” | “−5.52” | “−0.60” | “−3.42” | “−7.27” | “+0.11” |
| Adiponectin, fold increase | “4.12” | “4.44” | “1.11” | “3.62” | “4.54” | “1.00” |

Source: [Holleboom et al. (2026)](https://inventivapharma.com/wp-content/uploads/Metabolic-Benefits-of-Lanifibranor-in-Patients-With-and-Without-Type-2-Diabetes_ParisMASH_poster.pdf)

<a id="topic-3.1.2.8.3-13"></a>

###### Adiponectin and inflammatory markers: adjusted mean change at week 24, completers in the full analysis population

> “Laboratory Measures at Week 24 among the Patients in the Full Analysis Population Who Completed the Trial.”
> “There was a dose-dependent increase in serum adiponectin level, which suggests that there was an improvement in adipose-tissue function.”
> “Adjusted mean absolute changes and 95% confidence intervals were derived with the use of mixed models for repeated measures”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Change from baseline (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
| --- | --- | --- | --- |
| Adiponectin, μg/ml | “17.12 (14.29 to 19.96)” | “11.95 (8.97 to 14.94)” | “−0.35 (−3.20 to 2.50)” |
| High-sensitivity CRP, mg/liter | “−1.37 (−2.28 to −0.46)” | “−2.05 (−2.97 to −1.13)” | “0.11 (−0.81 to 1.03)” |
| Fibrinogen, g/liter | “−0.10 (−0.24 to 0.05)” | “−0.17 (−0.32 to −0.02)” | “0.02 (−0.12 to 0.17)” |
| α2-Macroglobulin, g/liter | “0.13 (0.04 to 0.22)” | “0.15 (0.06 to 0.24)” | “0.05 (−0.04 to 0.13)” |
| Haptoglobin, g/liter | “−0.07 (−0.13 to 0)” | “−0.05 (−0.12 to 0.01)” | “0.05 (−0.01 to 0.12)” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-14"></a>

###### Noninvasive tests of fibrosis, apoptosis, and steatosis: completers in the full analysis population

> “Mean transient elastography values decreased by 1.7 in the 1200-mg lanifibranor group, 1.0 in the 800-mg lanifibranor group, and 0.7 in the placebo group. The results with respect to controlled attenuation parameter were in a similar direction, with greater decreases in the lanifibranor groups than in the placebo group (Table S9).”
> “The histologic results are supported by apparent improvements in several relevant metabolic, inflammatory, and fibrogenesis markers, including Pro-C3 and liver stiffness, but other markers of fibrosis (scores on the Enhanced Liver Fibrosis test and Fibrosis-4 index) did not improve. However, as changes in biomarkers are not fully validated as surrogates of histologic change, these results should be interpreted with caution, particularly in short-term trials.”
> “Laboratory Measures at Week 24 among the Patients in the Full Analysis Population Who Completed the Trial.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Change from baseline in exploratory end points (95% CI) | Lanifibranor 1200 mg (N=77) | Lanifibranor 800 mg (N=77) | Placebo (N=74) |
| --- | --- | --- | --- |
| Pro-C3, μg/liter | “−1.79 (−3.07 to −0.52)” | “−3.93 (−5.26 to −2.61)” | “−1.01 (−2.30 to 0.28)” |
| TIMP-1 to MMP-2 ratio | “−0.75 (−0.93 to −0.57)” | “−0.69 (−0.88 to −0.50)” | “−0.11 (−0.29 to 0.08)” |
| Cytokeratin 18 M30, pmol/liter | “−315.55 (−441.55 to −189.55)” | “−331.71 (−463.78 to −199.65)” | “−105.03 (−232.86 to 22.80)” |
| Enhanced Liver Fibrosis test score | “0.11 (−0.04 to 0.26)” | “−0.19 (−0.35 to −0.04)” | “−0.08 (−0.23 to 0.06)” |
| Fibrosis-4 index score | “0.03 (−0.13 to 0.19)” | “0 (−0.17 to 0.16)” | “−0.03 (−0.19 to 0.13)” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.3-15"></a>

###### Cardiometabolic secondary and post hoc analyses: scope and multiplicity

> “This manuscript reports the results of several secondary objectives of the NATIVE trial, that were prespecified in the protocol and the Statistical Analysis Plan (SAP), including the effect of lanifibranor 1200 mg/day and 800 mg/day versus placebo on CMH markers, evaluated after 24 weeks of treatment (EOT) compared to baseline, and for some markers also at TW4.”
> “No multiplicity adjustments were performed for the analyses presented in this paper, that are considered exploratory.”
> “Limitations may include the fact that patients who meet study entry criteria may not represent all patients seen in varying practice environments; analyses were post-hoc of available data”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-16"></a>

###### Insulin resistance and glycemic control: adjusted mean difference versus placebo at end of treatment

> “Fasting insulin levels (FIL) significantly decreased with lanifibranor in the overall population; adjusted mean difference versus placebo [AMD] at end of treatment [EOT] was −79 pmol/L (95% confidence interval [CI]: −112 to −47, p < 0.001) with lanifibranor 1200 mg; −83 pmol/L (95%CI: −115 to −51, p < 0.001) with 800 mg.”
> “Overall, AMD was −0.8 mmol/L (95%CI: −1.2 to −0.5, p < 0.001) with 1200 mg and −1.0 mmol/L (95%CI: −1.4 to −0.7, p < 0.001) with 800 mg. With T2D, AMD in hemoglobin A1c (HbA1c) at EOT was −0.7% (95%CI: −1.0 to −0.4, p < 0.001) in both active arms. Overall, HbA1c was −0.5% (95%CI: −0.6 to −0.3, p < 0.001) with both lanifibranor 1200 mg and 800 mg (Table 1, Fig. 1F).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-17"></a>

###### Glycemic status in participants with prediabetes or normoglycemia at baseline: post hoc analysis

> “With prediabetes, FG decreased at EOT to <5.6 mmol/L in 71% (95%CI: 48 to 95, p = 0.009) of patients on lanifibranor 1200 mg, 67% (95%CI: 45 to 88, p = 0.013) on 800 mg versus 11% (95%CI: 0 to 32) on placebo, indicating return to normoglycemia in the majority of lanifibranor-treated patients.”
> “Conversely, among 83 patients with normoglycemia at baseline, 0% with lanifibranor 1200 mg and 800 mg progressed to prediabetes at EOT, versus 26% (95%CI: 10 to 41, both p < 0.01) in the placebo arm (Supplementary Table 3).”
> “Further post-hoc analyses, i.e., not pre-specified in the SAP, included: the effects of therapy in the subgroups of patients with and without overt T2D; in patients with prediabetes at baseline”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-18"></a>

###### Lipids and apolipoproteins: adjusted mean difference versus placebo at end of treatment

> “Fasting total serum triglycerides (TG) levels decreased significantly with lanifibranor compared to placebo, with an AMD at EOT of −0.5 mmol/L (95%CI: −0.8 to −0.3, equivalent to −44.3 mg/dL, p < 0.001) with both lanifibranor 1200 mg and 800 mg groups (Table 1).”
> “Among the 109 patients with high baseline TG values (>1.7 mmol/L, 150.5 mg/dL), 60% and 70% on lanifibranor 1200 mg and 800 mg, respectively, improved to low-risk TG levels of ≤1.7 mmol/L at EOT, versus 27% on placebo (Supplementary Fig. 1).”
> “No significant LDL-C change was observed with either lanifibranor dose versus placebo (Table 1, Fig. 1C).”
> “Lanifibranor significantly reduced APO-B with an AMD at EOT of −10 mg/dL (95%CI: −15 to −4, p < 0.001) with both doses (Table 1, Fig. 1D)”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-19"></a>

###### Systemic inflammation and ferritin: adjusted mean difference versus placebo at end of treatment

> “With lanifibranor 1200 mg and 800 mg respectively, AMD at EOT was −1.5 mg/L (95%CI: −2.8 to −0.2, p = 0.026) and −2.2 mg/L (95%CI: −3.5 to −0.9, p = 0.001)”
> “At EOT, levels decreased significantly with lanifibranor (AMD at EOT: −84.2 µg/L [95%CI: −125.2 to –43.3], −71.8 µg/L [95%CI: −112.6 to −31.0] for lanifibranor 800 mg and 1200 mg, respectively, both p < 0.001), but were unchanged with placebo (Table 1, Fig. 1H).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-20"></a>

###### Blood pressure: adjusted mean difference versus placebo at end of treatment

> “From TW4 and maintained during treatment, diastolic BP (DBP) decreased with both lanifibranor doses (AMD at EOT was −2.5 mmHg [95%CI: −5.5 to 0.6, p = 0.110] with lanifibranor 1200 mg and −3.9 mmHg [95%CI: −6.9 to −0.9, p = 0.012] with 800 mg, [Table 1, Fig. 1I]). Systolic BP did not change significantly.”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-21"></a>

###### Hepatic steatosis by histology and controlled attenuation parameter

> “Histological steatosis improved significantly at EOT with lanifibranor versus placebo, with more than 35% of patients improving by at least 2 grades with lanifibranor versus 5% with placebo (Fig. 2A).”
> “Controlled attenuation parameter (CAP™) similarly decreased significantly at EOT with lanifibranor (AMD at EOT was −23 dB/m [95%CI: −41 to −5, p = 0.012] with 1200 mg and −16 dB/m [95%CI: −33 to 1, p = 0.070] with 800 mg [Table 1]) but not with placebo (Fig. 2C).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-22"></a>

###### Cardiometabolic and hepatic markers by weight change group: post hoc analysis

> “In pooled lanifibranor arms, all CMH markers, i.e., steatosis, HOMA-IR, FIL, lipids (HDL-C, TG, APO-B, APO-C3, APO-B/APO-A), FG, hs-CRP, ferritin and DBP, as well as liver tests (ALT, AST, gamma-glutamyl transferase [GGT]), improved to the same degree in the three weight-change groups. In contrast, placebo-treated patients with increased weight at EOT had unchanged or worsening values of these markers.”
> “Further post-hoc analyses, i.e., not pre-specified in the SAP, included”
> “the correlation between weight changes (both continuous and by weight-change group, i.e., <2.5%, 2.5−5% and ≥5% increase from baseline) under lanifibranor and placebo, separately, and improvement in CMH markers”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-23"></a>

###### Adiponectin response and histologic improvement

> “Higher increase of adiponectin levels was observed in the lanifibranor 1200 mg (mean fold 4.5) compared to lanifibranor 800 mg (3.8) at EOT, 86% of patients on lanifibranor 800 mg had moderate (58%) or high (29%) increase and 95% of those on 1200 mg had moderate (52%) or high (42%) increase. With placebo only 10% had moderate, and none high increase (Supplementary Table 6).”
> “Absolute and categorical (fold change) adiponectin increase also correlated with improvement of liver histological endpoints for disease activity, i.e., CRN-NAFLD activity score (NAS) and individual activity components (ballooning and inflammation), and with improvement in fibrosis stage (38% versus 57% for adiponectin increase ≤4- versus >4-fold, respectively) (Supplementary Table 8, Fig. 5A−D).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-24"></a>

###### Cardiometabolic markers in obese and non-obese participants

> “Of 247 patients enrolled, 161 (65%) patients were obese (BMI ≥ 30) and 86 (35%) patients had a BMI < 30 at baseline (Supplementary Table 1). Overall, the effects of lanifibranor therapy versus placebo on markers of CMH and on liver tests were similar for obese and non-obese patients (Supplementary Table 13).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.3-25"></a>

###### Adiponectin fold change at end of treatment by arm and relation to weight change: congress poster

> “Circulating ADP levels were measured at baseline (BL) and end of treatment (EOT) in 211 patients; weight-based CMH analyses were performed in 217 completers.”
> “With lanifibranor, 87% of patients had an ADP increase at EOT vs only 10% of placebo patients; among placebo patients, all increases were < 4-fold.”
> “Lanifibranor induced robust adiponectin increases that were associated with improvements in MASH histology and cardiometabolic health. These effects were independent of body-weight change.”

Source: [Rinella et al. (2026b)](https://inventivapharma.com/wp-content/uploads/ADP-and-Weight-Gain-Correlation-Poster_EASL2624.pdf)

| Fold adiponectin at week 24 | Placebo | Lanifibranor 800 mg | Lanifibranor 1200 mg | Lanifibranor pooled |
| --- | --- | --- | --- | --- |
| Number of participants | “72” | “66” | “73” | “139” |
| Mean (SD) | “1.1 ± 0.3” | “3.8 ± 3.1” | “4.5 ± 3.5” | “4.2 ± 3.3” |
| Unchanged | “65 (90%)” | “9 (14%)” | “4 (5%)” | “13 (9%)” |
| Fold 1.5 to 4 | “7 (10%)” | “38 (58%)” | “38 (52%)” | “76 (55%)” |
| Fold more than 4 | “0 (0.0%)” | “19 (29%)” | “31 (42%)” | “50 (36%)” |

Source: [Rinella et al. (2026b)](https://inventivapharma.com/wp-content/uploads/ADP-and-Weight-Gain-Correlation-Poster_EASL2624.pdf)

<a id="topic-3.1.2.8.3-26"></a>

###### Serum biomarker signatures of histologic response: pooled lanifibranor arms

> “Patients receiving lanifibranor were pooled, and those with liver biopsies were selected (n = 142). A panel of 65 biomarkers were evaluated by assessing baseline and absolute as well as relative changes at the end of treatment.”
> “The biomarkers included in E1 score (baseline adiponectin and ferritin; delta of matrix metalloproteinase 9 and transferrin), E2 score (baseline cytokeratin 18 Fragment M65; delta of hyaluronic acid, fructosamine, and alanine aminotransferase), and E3 score (baseline cytokeratin 18 Fragment M65 and gamma-glutamyl transferase; delta of aspartate aminotransferase, insulin, and urea) represented metabolic, apoptotic, and fibrosis aspects of the disease. These signatures provided good accuracy for the noninvasive identification of histologic response under lanifibranor with area under the receiver operating characteristic curve at 0.81 ± 0.08 for E1 score, 0.80 ± 0.08 for E2 score, and 0.81 ± 0.08 for E3 score.”
> “Results from this analysis show evidence that baseline values and changes in selected serum biomarkers can aid in predicting histologic response in MASH under lanifibranor treatment.”

Source: [Boursier et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40107637/)

<a id="topic-3.1.2.8.3-27"></a>

###### Liver sinusoidal endothelial cell capillarisation (CD34 staining) at baseline and week 24

> “Among the latter, 173 patients had baseline liver tissue available for CD34 staining, including 163 with liver tissue also available at week 24.”
> “In patients with MASH randomised into the NATIVE trial, 24-week treatment with lanifibranor at both dosages had no effect on the density of CD34-positive vessels (Fig. 5A). Improvement in periportal score was more common in patients treated with lanifibranor than in those treated with placebo, with a dose–response effect (placebo: 7.5%. lanifibranor 800 mg: 18.5%. lanifibranor 1,200 mg: 23.2%. p = 0.025, Fig. 5C). Patients with lanifibranor treatment had less worsening of lobular score (placebo: 39.6%, lanifibranor 800 mg: 18.5%, lanifibranor 1,200 mg: 23.2%; p = 0.028, Fig. 5F).”

Source: [Rautou et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12142333/)

<a id="topic-3.1.2.8.3-28"></a>

###### Histologic and metabolic response by PNPLA3 genotype: congress poster

> “Of these, 219 patients consented to genotyping for the PNPLA3 rs738409 SNP. Sixty five were II, 105 IM and 49 MM, which is highest risk for disease severity and progression.”
> “There was no significant difference in response to lanifibranor by PNPLA3 genotype, despite the fact that MM genotype patients had more activity on biopsy than the II or IM patients (82% NAS≥6, vs 74%, 70%), while there was no difference in fibrosis.”
> “The efficacy of lanifibranor on both liver histology and markers of cardiometabolic health appears to be independent of PNPLA3 status, despite MM genotype patients having more severe activity on liver biopsy.”

Source: [Griffel et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD23-PNPLA3_V1.0_20231013.pdf)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### SF-36 and Flinders Fatigue Scale at week 24

> “With regard to quality of life, no substantial changes from baseline in the various dimensions of the Medical Outcomes Study 36-Item Short-Form Health Survey and the score on the Flinders Fatigue Scale were observed at week 24 (Table S10).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Adverse event overview: full analysis population, treatment period

> “Overview of Adverse Events That Occurred during the Treatment Period (Full Analysis Population).”
> “The treatment period was defined as the period after the first dose up to 28 days after the last dose.”
> “Most adverse events were mild or moderate in severity (Table 3).”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Event, number (percent) | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) |
| --- | --- | --- | --- |
| At least 1 adverse event | “62 (75)” | “59 (71)” | “50 (62)” |
| Mild | “54 (65)” | “51 (61)” | “42 (52)” |
| Moderate | “28 (34)” | “20 (24)” | “22 (27)” |
| Severe | “3 (4)” | “3 (4)” | “3 (4)” |
| Adverse event related to active drug or placebo, as assessed by the investigator | “23 (28)” | “25 (30)” | “19 (23)” |
| Adverse event that led to permanent discontinuation of the trial regimen | “3 (4)” | “4 (5)” | “3 (4)” |
| Adverse event related to active drug or placebo that led to discontinuation | “2 (2)” | “1 (1)” | “2 (2)” |
| Serious adverse event | “7 (8)” | “3 (4)” | “3 (4)” |
| Death | “0” | “0” | “0” |
| Serious adverse event related to active drug or placebo | “0” | “0” | “2 (2)” |
| Serious postprocedural condition linked to biopsy procedure | “3 (4)” | “1 (1)” | “0” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-2"></a>

###### Most frequent adverse events by arm: full analysis population

> “Overview of Adverse Events That Occurred during the Treatment Period (Full Analysis Population).”
> “Adverse events are listed for those that occurred in more than 5% of patients in either lanifibranor group.”
> “Nausea, diarrhea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo.”
> “Fatigue included asthenia.”
> “Anemia included iron deficiency anemia and decreased hemoglobin level.”
> “Increase in aminotransferase level included increased alanine aminotransferase level, increased aspartate aminotransferase level, or abnormal liver function test result.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Adverse event, number (percent) | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) |
| --- | --- | --- | --- |
| Diarrhea | “10 (12)” | “8 (10)” | “1 (1)” |
| Fatigue | “11 (13)” | “3 (4)” | “8 (10)” |
| Nausea | “7 (8)” | “8 (10)” | “3 (4)” |
| Weight gain | “7 (8)” | “8 (10)” | “0” |
| Peripheral edema | “7 (8)” | “5 (6)” | “2 (2)” |
| Headache | “7 (8)” | “4 (5)” | “4 (5)” |
| Abdominal pain | “5 (6)” | “4 (5)” | “4 (5)” |
| Dizziness | “6 (7)” | “2 (2)” | “3 (4)” |
| Anemia | “6 (7)” | “1 (1)” | “0” |
| Constipation | “5 (6)” | “3 (4)” | “6 (7)” |
| Increase in aminotransferase level | “3 (4)” | “5 (6)” | “1 (1)” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-3"></a>

###### Serious adverse events by arm: full analysis population

> “Overview of Adverse Events That Occurred during the Treatment Period (Full Analysis Population).”
> “There were two serious adverse events (mild heart failure and urticaria, both in the placebo group) that were determined by the investigator to be related to the placebo.”
> “There were two suspected unexpected serious adverse reactions; one patient had mild cardiac failure, and one patient had moderate urticaria.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

| Other serious adverse event, number (percent) | Lanifibranor 1200 mg (N=83) | Lanifibranor 800 mg (N=83) | Placebo (N=81) |
| --- | --- | --- | --- |
| Wrist fracture | “0” | “0” | “1 (1)” |
| Unstable angina | “1 (1)” | “0” | “0” |
| Heart failure | “0” | “0” | “1 (1)” |
| Gastroenteritis | “1 (1)” | “0” | “0” |
| Pyelonephritis | “1 (1)” | “0” | “0” |
| Pancreatitis | “0” | “1 (1)” | “0” |
| Undifferentiated connective tissue disease | “0” | “1 (1)” | “0” |
| Urticaria | “0” | “0” | “1 (1)” |
| Foot operation | “1 (1)” | “0” | “0” |

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-4"></a>

###### Discontinuations and severe adverse events

> “The assigned regimen was discontinued because of adverse events in three patients (4%) in the 1200-mg lanifibranor group, in four patients (5%) in the 800-mg lanifibranor group, and in three patients (4%) in the placebo group.”
> “In each trial group, three patients (4%) had a severe adverse event during the treatment period (defined as the period after the first dose up to 28 days after the last dose).”
> “One patient had mild cardiac failure, and one patient had mild diarrhea, abdominal pain, and dizziness.”
> “One patient had moderate diarrhea.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-5"></a>

###### Peripheral edema: journal report

> “Peripheral edema that was assessed by the investigator as being related to the active drug or placebo occurred in four patients (2%) in the lanifibranor groups (two in each group) and in no patient in the placebo group during the treatment period. One patient had severe peripheral edema but recovered after discontinuing the 1200-mg regimen of lanifibranor for 12 days; treatment was resumed without reoccurrence of edema.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-6"></a>

###### Peripheral edema: character, management, and sex of participants with drug-related cases, company presentation

> “Peripheral edema (bilateral ankle edema): usually mild, in most cases no treatment was required, a few patients received diuretics.”
> “4 cases were considered study drug related by the investigator (2 at 800 and 1200 mg each). One case of severe intensity, which resolved by stopping treatment (lanifibranor 1200mg) for 12 days, without reoccurrence when the study treatment was resumed. All were female patients.”

Source: [Inventiva investor and analyst day presentation (2025)](https://inventivapharma.com/wp-content/uploads/Inventiva-Investor-and-Analyst-Day-10-08-2025.pdf)

<a id="topic-3.1.2.8.5-7"></a>

###### Body weight: mean change from baseline at week 24

> “A mean increase of 2.7 kg (3.1%) from baseline in body weight was observed among the patients in the 1200-mg lanifibranor group, and a mean increase of 2.4 kg (2.6%) was observed among the patients in the 800-mg lanifibranor group (Fig. S7).”
> “This improvement in adipose tissue function is most likely the main reason for the observed increase in body weight.”
> “Lanifibranor induced a histologic improvement despite this weight gain, which could be explained by the role of adipose-tissue dysfunction rather than overweight per se in the pathophysiology of NASH”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-8"></a>

###### Body weight: distribution of weight change at end of treatment, pooled lanifibranor arms

> “patients had an average weight gain of 2.5 kg, with 49% gaining ≥2.5% weight”
> “Weight change showed considerable interindividual variability: at EOT, 51% of patients in pooled lanifibranor arms had stable weight (≤2.5% increase), 16% had moderate increase (2.5−5%), and 33% had ≥5% increase from baseline; with placebo 84% had stable weight, but 16% had >2.5% weight increase (Supplementary Fig. 3).”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.5-9"></a>

###### Body weight: weight change category at week 24 by arm, completers, congress poster

> “weight-based CMH analyses were performed in 217 completers”
> “only two weight change groups for placebo due to few patients >5%.”

Source: [Rinella et al. (2026b)](https://inventivapharma.com/wp-content/uploads/ADP-and-Weight-Gain-Correlation-Poster_EASL2624.pdf)

| Weight at week 24 | Placebo | Lanifibranor 800 mg | Lanifibranor 1200 mg | Lanifibranor pooled |
| --- | --- | --- | --- | --- |
| Number of participants | “73” | “71” | “73” | “144” |
| Stable (2.5% or less) | “61 (84%)” | “41 (58%)” | “32 (44%)” | “73 (51%)” |
| Increase (more than 2.5%), placebo only | “12 (16%)” | “–” | “–” | “–” |
| Increase (2.5% to 5%) | “–” | “9 (13%)” | “14 (19%)” | “23 (16%)” |
| Increase (more than 5%) | “–” | “21 (30%)” | “27 (37%)” | “48 (33%)” |

Source: [Rinella et al. (2026b)](https://inventivapharma.com/wp-content/uploads/ADP-and-Weight-Gain-Correlation-Poster_EASL2624.pdf)

<a id="topic-3.1.2.8.5-10"></a>

###### Anemia and hemoglobin

> “Anemia was reported in six patients (7%) in the 1200-mg lanifibranor group, with the hemoglobin levels returning to pretreatment values after either investigator-initiated iron supplementation or discontinuation of lanifibranor. A relative reduction in hemoglobin levels of 5 to 6% from baseline was observed in the lanifibranor groups, as compared with a 1% reduction in the placebo group (Fig. S8).”
> “A reduction in hemoglobin levels was observed in the lanifibranor groups, a finding that is consistent with those in previous reports of other compounds with PPARγ agonism; such a reduction has several potential underlying mechanisms.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-11"></a>

###### Heart failure and NT-proBNP

> “One patient in the 1200-mg lanifibranor group was reported by the investigator to have nontreatment-related mild heart failure that did not lead to further investigation or hospitalization.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

> “N-terminal pro b-type natriuretic peptide (NT-proBNP) increased with both lanifibranor doses; AMD at EOT was 8.4 pmol/L (71 pg/mL) with lanifibranor 1200 mg and 4.0 pmol/L (34 pg/mL) with 800 mg (Table 1, Fig. 1J), this increase being correlated with weight increase (Supplementary Table 4, Fig. 3G).”
> “While PPARγ-associated weight gain is thus indicative of maturation of adipose tissue, some contributing effect on fluid retention is suggested by the treatment effect on NT-proBNP.”
> “There was no clinical evidence for congestion in patients on lanifibranor in NATIVE.”

Source: [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.8.5-12"></a>

###### Kidney function and bone turnover

> “Kidney function (markers included creatinine and urea levels and estimated glomerular filtration rate) (Table S11) and bone turnover (markers included osteocalcin level and beta-CrossLaps value [the level of β-isomer of the C-terminal telopeptide of type I collagen, as measured with a CrossLaps osteometer, Biotech]) (Table S12) were not impaired.”

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205)

<a id="topic-3.1.2.8.5-13"></a>

###### Serious adverse events: registry results

> “On or after the first dose of treatment up to 30 days post last dose.”
> “Term from vocabulary, MedDRA 20.0”

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

| Serious adverse event, affected / at risk (%) | IVA337 1200mg | IVA337 800mg | Placebo |
| --- | --- | --- | --- |
| All-cause mortality | “0/83 (0.00%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Total serious adverse events | “7/83 (8.43%)” | “3/83 (3.61%)” | “3/81 (3.70%)” |
| Angina unstable | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Cardiac failure | “0/83 (0.00%)” | “0/83 (0.00%)” | “1/81 (1.23%)” |
| Pancreatitis | “0/83 (0.00%)” | “1/83 (1.20%)” | “0/81 (0.00%)” |
| Pneumobilia | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Gastroenteritis | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Pyelonephritis | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Post procedural haematoma | “2/83 (2.41%)” | “1/83 (1.20%)” | “1/81 (1.23%)” |
| Post procedural haemorrhage | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Procedural pain | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |
| Wrist fracture | “0/83 (0.00%)” | “0/83 (0.00%)” | “1/81 (1.23%)” |
| Undifferentiated connective tissue disease | “0/83 (0.00%)” | “1/83 (1.20%)” | “0/81 (0.00%)” |
| Urticaria | “0/83 (0.00%)” | “0/83 (0.00%)” | “1/81 (1.23%)” |
| Foot operation | “1/83 (1.20%)” | “0/83 (0.00%)” | “0/81 (0.00%)” |

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="topic-3.1.2.8.5-14"></a>

###### Other adverse events at the 5% reporting threshold: registry results

> “Frequency Threshold for Reporting Other Adverse Events”
> “Indicates events were collected by non-systematic assessment”

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

| Other adverse event, affected / at risk (%) | IVA337 1200mg | IVA337 800mg | Placebo |
| --- | --- | --- | --- |
| Total | “60/83 (72.29%)” | “48/83 (57.83%)” | “30/81 (37.04%)” |
| Diarrhoea | “10/83 (12.05%)” | “8/83 (9.64%)” | “1/81 (1.23%)” |
| Nausea | “7/83 (8.43%)” | “8/83 (9.64%)” | “3/81 (3.70%)” |
| Constipation | “5/83 (6.02%)” | “3/83 (3.61%)” | “6/81 (7.41%)” |
| Fatigue | “11/83 (13.25%)” | “3/83 (3.61%)” | “8/81 (9.88%)” |
| Oedema peripheral | “7/83 (8.43%)” | “5/83 (6.02%)” | “2/81 (2.47%)” |
| Viral upper respiratory tract infection | “3/83 (3.61%)” | “3/83 (3.61%)” | “5/81 (6.17%)” |
| Weight increased | “7/83 (8.43%)” | “8/83 (9.64%)” | “0/81 (0.00%)” |
| Transaminases increased | “3/83 (3.61%)” | “5/83 (6.02%)” | “1/81 (1.23%)” |
| Headache | “7/83 (8.43%)” | “4/83 (4.82%)” | “4/81 (4.94%)” |
| Dizziness | “6/83 (7.23%)” | “2/83 (2.41%)” | “3/81 (3.70%)” |

Source: [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: duration, sample size, histology reading, and sponsor role

- Treatment lasted 24 weeks; the protocol states that 6 months is sufficient in a proof-of-concept study and limits the time on placebo.
- The protocol planned 225 randomized participants (75 per arm) for at least 80% power with a two-sided alpha of 0.025, assuming a placebo responder rate of 10% and an excess responder rate of 20%. The placebo response on the primary endpoint was 33% in the multiple imputation analysis of the journal report and 27% in the intention-to-treat population of the company topline release. A total of 247 participants were randomized (83, 83, and 81) out of 868 screened.
- All biopsy samples were read by one pathologist who was unaware of timing and group assignment.
- No fibrosis-stage inclusion criterion was set other than exclusion of cirrhosis; 188 participants (76%) had stage F2 or F3 fibrosis, and results in this group come from a subgroup analysis.
- The journal report states that the validity of the SAF-A score as a surrogate for long-term outcomes “warrants further study”, and that changes in noninvasive biomarkers should be interpreted with caution, “particularly in short-term trials”.
- The sponsor designed the trial, monitored the sites, collected the data, and analyzed the data.

Source: [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf); [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205); [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf); [Francque et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33038502/)

<a id="topic-3.1.2.9-2"></a>

###### Summary: missing biopsies, analysis methods, protocol changes, and figures that differ by source

- Week 24 biopsies were missing for 34 participants (11 at 800 mg, 9 at 1200 mg, and 14 with placebo). The protocol specified that an amendment would be submitted to increase the sample size if end-of-study slides were unavailable or uninterpretable in more than 5% of participants.
- The protocol's primary rule counted missing data as nonresponse; the journal report's primary analysis used multiple imputation. With multiple imputation, the primary endpoint was met by 55% with 1200 mg and 48% with 800 mg versus 33% with placebo (P=0.007 and P=0.07). The company topline release (intention-to-treat, all randomized) gives 49% (P=0.004) and 41% (P=0.061) versus 27%, and the registry, counting missing data as nonresponse, gives 41 of 83, 34 of 83, and 22 of 81 responders. The journal report states that nonresponder imputation and complete-case results were similar.
- No multiplicity adjustments were defined for secondary and exploratory end points. The cardiometabolic analyses of Cooreman et al. had no multiplicity adjustment, are considered exploratory, and include post hoc analyses.
- Protocol version 5.0, dated July 9, 2019, updated the secondary endpoints. The registry states that the last participant was recruited in March 2019, and the journal report gives a screening period of February 2017 through July 2019.
- The selection period is 3 days to 4 weeks in the protocol and 10 days to 4 weeks in the registry.
- Discontinuations for adverse events are 3 (4%), 4 (5%), and 3 (4%) in the journal report (1200 mg, 800 mg, placebo) and 3, 3, and 3 in the registry participant flow, which lists one further 800 mg participant under “Withdrawal by patient and adverse event non fatal”.

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205); [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf); [Inventiva NATIVE topline results release (2020)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-NATIVE-top-line-results-EN-15062020.pdf); [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results); [ClinicalTrials.gov NCT03008070 API record](https://clinicaltrials.gov/api/v2/studies/NCT03008070); [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070); [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="topic-3.1.2.9-3"></a>

###### Summary: enrolled population and generalizability

- Of 247 participants, 232 (94%) were White and 103 (42%) had type 2 diabetes. By registry region of enrollment, 55 were enrolled in Bulgaria, 39 in France, and 36 in the United States.
- The protocol required GLP-1 receptor agonists, vitamin E, fibrates, and PPAR gamma agonists to be stopped before randomization, and the registry excluded participants with type 2 diabetes on insulin, HbA1c >8.5%, or body mass index >45 kg/m2.
- Cooreman et al. state that participants who meet study entry criteria may not represent all patients seen in varying practice environments.

Source: [Francque et al. (2021)](https://www.nejm.org/doi/full/10.1056/NEJMoa2036205); [ClinicalTrials.gov NCT03008070 results](https://clinicaltrials.gov/study/NCT03008070?tab=results); [Inventiva NATIVE protocol (2019)](https://cdn.clinicaltrials.gov/large-docs/70/NCT03008070/Prot_002.pdf); [ClinicalTrials.gov NCT03008070](https://clinicaltrials.gov/study/NCT03008070); [Cooreman et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11087475/)

<a id="heading-3.1.3"></a>

#### 3.1.3 LEGEND

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.1-2"></a>

###### Primary and secondary objectives in the statistical analysis plan

> “The primary objective of this study is to assess the effect of lanifibranor alone compared to placebo and the effect of lanifibranor in combination with empagliflozin compared to placebo on Haemoglobin A1C (HbA1c) after a 24-week treatment period.”
> “and to assess the safety and tolerability of lanifibranor alone and in combination with empagliflozin during the 24-week treatment period and the 4-week follow-up period.”

Source: [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf)

<a id="topic-3.1.3.1-3"></a>

###### Objectives in the protocol: confirming the NATIVE glycemic effect and testing the empagliflozin combination

> “Confirm as primary objective the lanifibranor effect versus placebo on glycemic control observed in the NATIVE Phase 2b study (NCT03008070)”
> “Confirm a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control (i.e., conservation of the effect when associated with an SGLT2 inhibitor, no deleterious effect, no negative interaction on glycemic control)”
> “This study will allow evaluation of the effect of lanifibranor in combination with an SGLT2 inhibitor on body weight, peripheral edema, and anemia as safety endpoints.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.1-4"></a>

###### Rationale in the protocol for combining lanifibranor with an SGLT2 inhibitor

> “In addition, the combination of lanifibranor with an SGLT2 inhibitor may improve tolerability of the PPAR agonist. While lanifibranor has an overall favorable safety profile, weight gain, peripheral edema and anemia have been observed in Phase 2 studies, mainly in female patients.”
> “SGLT2 inhibitors induce weight loss and have a diuretic effect. They have also been shown to increase hematopoiesis.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.1-5"></a>

###### Proof-of-concept purpose and plans for the combination stated in the annual report

> “The LEGEND trial was intended to demonstrate proof of concept and the potential additional benefits of the combination between lanifibranor and empagliflozin and the possibility to address the weight gain observed in some patients treated with lanifibranor alone.”
> “We do not expect to further study the combination of lanifibranor and empagliflozin but expect to include the safety data from the LEGEND trial in a potential submission for marketing approval.”

Source: [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study dates in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-06-29”
> “Primary Completion (Actual) 2024-05-08”
> “Study Completion (Actual) 2024-06-04”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.2-2"></a>

###### Registered locations

> “This study has 42 locations”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.2-3"></a>

###### Planned sites in the protocol synopsis

> “Approximately 30 sites across Europe and the United States of America (USA)”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.2-4"></a>

###### Recruitment period, screening, and results posting in the ClinicalTrials.gov results

> “Recruitment of patients started in June 2022 and last patient was recruited in November 2023. A total of 213 patients were screened for the study.”
> “Results First Posted 2026-09-09”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.2-5"></a>

###### Interim analysis data cut-off and date in the statistical analysis plan

> “An interim analysis will be conducted once approximately half of the planned patients will be randomized, and have either completed the 24-week treatment period or prematurely discontinued from treatment earlier as of 31-Jan-2024.”
> “The interim analysis was conducted on March 2024”

Source: [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Three-arm design with an open-label combination arm in the protocol

> “The study is designed as a multinational, multicenter, three-arm, randomized, double-blind for lanifibranor and placebo, open-label for the combination lanifibranor plus empagliflozin, placebo-controlled, 24-week treatment study followed by a 4-week post-treatment visit.”
> “A total of 63 patients are planned to be randomized 1:1:1 to receive:”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.3-2"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |
| Primary purpose | “Treatment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “39” |

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.3-3"></a>

###### Stratified randomization and sex quotas in the protocol

> “Randomization will be stratified by 2 stratifying factors: HbA1c at Screening (< 7.5%, ≥ 7.5%) and by sex (Male, Female), because these factors are considered important prognostic covariates.”
> “Moreover, at least 40% males and at least 40% females will be randomized.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.3-4"></a>

###### Rationale in the protocol for blinding the lanifibranor and placebo arms only

> “For that reason, a double-blind design was chosen for the lanifibranor and matching placebo arm to allow the assessment of the effect of lanifibranor versus placebo on HbA1c (primary endpoint) and other endpoints for glycemic control, liver tests, inflammatory markers, lipid parameters and body composition.”
> “For this purpose, an open-label design is deemed to be sufficient, for this proof-of-concept study.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.3-5"></a>

###### Interim analysis and stopping of recruitment

> “An interim analysis will be conducted once approximately half of the planned patients will be randomized, and have either completed the 24-week treatment period or prematurely discontinued from treatment earlier, that will constitute the Interim Analysis Set (IAS).”
> “Recruitment will be paused once the first half of the planned patients are randomized.”
> “Addition of an interim analysis (IA)”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

> “The primary endpoint was met. Therefore, recruitment has been stopped / not been re-initiated.”

Source: [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf)

> “Given that the primary endpoint of LEGEND was met, and statistically significant results were achieved on several key additional markers, the Company has decided to stop the recruitment as defined per protocol.”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="topic-3.1.3.3-6"></a>

###### Treatment and follow-up periods in the poster

> “24-week treatment + 4-week follow-up”
> “Double blind for L and P, open label for L+E,”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Key inclusion criteria in the ClinicalTrials.gov record

> “Male or female, aged ≥ 18 years at the time of signing informed consent”
> “Diagnosis of NASH, based on histology or cT1≥875ms assessed by LiverMultiScan or cT1≥825ms assessed by LiverMultiScan and hepatic fat content ≥ 10% assessed by MRI-PDFF at screening”
> “HbA1c at screening ≥ 7.0 and ≤ 10.0%, on diet alone, or on metformin and/or dipeptidyl peptidase 4 inhibitor (DPP-IVi) therapy. Both with doses to be stable for 3 months”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.4-2"></a>

###### Key exclusion criteria in the ClinicalTrials.gov record: cirrhosis, prior therapies, and BMI

> “Histologically documented liver cirrhosis (fibrosis stage F4)”
> “Patient currently receiving any approved treatment for NASH or obesity”
> “Current treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA), insulin or sulfonylurea or treatment within the last 3 months prior to Screening”
> “Patients on pioglitazone in the last 12 months prior to Screening.”
> “BMI>45 kg/m2 at screening”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.4-3"></a>

###### Diagnosis of MASH by historical histology or noninvasive methods

> “The diagnosis of non-cirrhotic MASH/NASH was based on historic histology evaluation or a combination of non-invasive methods including diagnostic methods including imaging.”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="topic-3.1.3.4-4"></a>

###### Imaging definitions of NASH and the glycemic criterion in the protocol

> “NASH defined as cT1 ≥ 825 ms assessed by LiverMultiScan® and hepatic fat content ≥ 10% assessed by MRI-PDFF”
> “HbA1c at screening ≥ 7.0 and ≤ 10.0%, on diet alone, or on metformin (≥ 1,000 mg/day), and/or dipeptidyl peptidase 4 inhibitor (DPP-IVi) therapy.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.4-5"></a>

###### Cirrhosis exclusion by biopsy or noninvasive criteria in the protocol

> “Histologically documented liver cirrhosis (fibrosis stage F4), based on a historical biopsy (within 12 months prior to Screening); or diagnosis of cirrhosis at Screening based on clinic biochemical and imaging criteria (FibroScan® value confirmed ≥ 14 kPa and FIB-4 > 3.25 provided to the site by the central lab)”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.4-6"></a>

###### Other exclusion criteria in the protocol: weight change, NT-proBNP, renal function, and CYP2C8 interacting drugs

> “Weight change > 5% in the 3 months prior to Screening”
> “NT-proBNP > 900 pg/mL”
> “Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value < 60 mL/min as determined by Modification of Diet in Renal Disease [MDRD]”
> “Treatment with strong inducers or inhibitors of CYP2C8. When administered chronically, they should be replaced 3 months before Screening visit.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.4-7"></a>

###### Autoimmune liver and thyroid disease exclusion following NATiV3 Data Monitoring Committee recommendations

> “Any patient with a predisposition to autoimmune liver disease, including:”
> “Addition of the exclusion criteria n°50 related to autoimmunity and addition of corresponding laboratory parameters”
> “To mimic the recommendations issued by the Data Monitoring Committee for the Phase 3 study, NATiV3”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.4-8"></a>

###### Key inclusion criteria in the poster

> “historical biopsy with NAS ≥4”
> “Screening HbA1c in 7-10%”
> “MASH was diagnosed per historical liver biopsy or MRI imaging (cT1 or cT1+PDFF).”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Treatment arms in the ClinicalTrials.gov record

> “Lanifibranor (800 mg/day): two film-coated tablets of 400 mg each, once-a-day (QD) with food. For oral use. QD for 24 weeks.”
> “Two lanifibranor placebo-matching tablets once-a-day (QD) with food. For oral use. QD for 24 weeks.”
> “Lanifibranor (800 mg/day): two film-coated tablets of 400 mg each plus one empagliflozin film-coated tablet of 10 mg (10mg/day), once-a-day (QD) with food. For oral use. QD for 24 weeks”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.5-2"></a>

###### Investigational treatments, dose adjustment, and interruption rules in the protocol

> “Tablets of lanifibranor 400 mg, administered on a daily dose of 800 mg lanifibranor or placebo, i.e., 2 tablets of 400 mg/placebo orally once daily (QD) during breakfast, for a total of 24 weeks”
> “Tablets of empagliflozin 10 mg/day administered orally once daily during breakfast, for a total of 24 weeks”
> “No lanifibranor or empagliflozin dose adjustment is allowed in the study.”
> “Interruption of the IMP(s) due to AEs is allowed as per the Investigator’s discretion and medical judgment for a maximum of 15 days, and should occur only once during the 24-week treatment period”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.5-3"></a>

###### Background antidiabetic therapy, prohibited medications, and rescue medication in the protocol

> “These medicines will be continued at stable doses during the entire study.”
> “CYP2C8 strong inducers (e.g. rifampin). However, if medically necessary, these drugs may be taken for a maximum duration of 3 weeks.”
> “Rescue medication is defined as use of any new or additional antidiabetic medication, or increase in the dose of background antidiabetic medication above the baseline dose.”
> “Sulfonylureas, metformin, DPP-IVi may all be given as rescue medication until the end of the trial.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Change in HbA1c as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary endpoint as registered

> “Absolute Change in HbA1c”
> “Effect of lanifibranor alone compared to placebo and the effect of lanifibranor in combination with empagliflozin compared to placebo on absolute change in HbA1c from baseline (Week 0) to Week 24”

Source: [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071)

<a id="topic-3.1.3.6.1-2"></a>

###### Primary endpoint in the protocol and the poster

> “Absolute change in HbA1c from baseline (Week 0) to Week 24”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

> “Change in HbA1c from baseline to treatment week (TW) 24 was the primary efficacy endpoint.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="topic-3.1.3.6.1-3"></a>

###### Rationale: confirming the HbA1c decrease seen in NATIVE participants with type 2 diabetes

> “In this study in NASH patients, a sub-analysis on those patients with T2DM at baseline (i.e., with baseline HbA1c > 6.5%), demonstrated significant improvements in glycemic control, with a substantial decrease in HbA1c under treatment with lanifibranor. The present LEGEND study is intended to confirm these preliminary findings.”
> “mean absolute changes from baseline at Week 24: -0.60% [SD: 0.54%] and -0.72% [SD: 0.65%] in the lanifibranor 800 mg and 1200 mg groups versus 0.10% [SD: 0.53%] in the placebo group”
> “As described in Section 2.1 the major purpose of this study is to confirm as primary objective the lanifibranor effect versus placebo on glycemic control observed in the NATIVE Phase 2b study.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.6.1-4"></a>

###### Rationale: shared metabolic pathways of NASH and type 2 diabetes

> “Therapeutic compounds that address the upstream metabolic and immune mediated pathways of NASH are also expected to be beneficial for T2DM.”
> “The strong association of NASH and T2DM, both being manifestations of the metabolic syndrome, provides a compelling rationale for investigating therapies that work on multiple mechanisms and combining treatments with synergistic effects.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.6.1-5"></a>

###### Primary estimand in the statistical analysis plan

> “The primary estimand is the comparison of lanifibranor alone and lanifibranor plus empagliflozin versus placebo on the change in HbA1c from baseline to end of treatment (Week 24), on the population initiating treatment with lanifibranor or lanifibranor plus empagliflozin, and excluding potential rescue medication and potential significant diet changes affecting metabolism (under the hypothetical strategy where patients would have continued their treatment during 24 weeks without rescue medication or significant diet change).”

Source: [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf)

<a id="topic-3.1.3.6.1-6"></a>

###### Secondary endpoints in the protocol: liver tests, glycemic response, body weight, and body composition

> “Change from baseline to Week 24 in liver tests (alanine aminotransferase [ALT], AST, gamma-glutamyl transferase (GGT), alkaline phosphatase [ALP], total and direct bilirubin)”
> “Binary endpoint defined as reaching HbA1c < 7.0% at Week 24, and no new antidiabetic treatment or increase in dosages of antidiabetic treatments”
> “Change from baseline to Week 24 in body weight”
> “Binary endpoint defined as reaching body weight increase ≥ 5% at Week 24”
> “Change from baseline to Week 24 in body composition as determined by MRI (including but not limited to: visceral adipose tissue [VAT], subcutaneous adipose tissue [SAT] and thigh SAT)”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.6.1-7"></a>

###### Adverse events of special interest in the protocol

> “Adverse Events of Special Interest (AESIs): anemia, heart failure, aminotransferase elevation, bone fracture, peripheral edema, cholelithiasis, hypoglycemia and ovulation resumption”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.6.1-8"></a>

###### Biomarker and MRI endpoints in the poster

> “Circulating biomarkers included liver enzymes, inflammation and fibrosis markers, lipid and glucose metabolism; MRI-based imaging included hepatic steatosis (PDFF), MASH composite disease activity and fibrosis (cT1), visceral (VAT) and subcutaneous (SAT) adipose tissue, spleen and liver volume; vital signs and safety were evaluated.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned sample size and power calculation in the protocol

> “Assuming an effect size of lanifibranor versus placebo of 0.60%, an expected SD of the change from baseline of 0.60%, a type I error of 0.05 (2-sided), an allocation ratio of 1:1, the required sample size per group is 21 patients with a power close to 90%.”
> “The total sample size is then 63 patients overall, distributed in 21 patients in each group.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

<a id="topic-3.1.3.7.1-2"></a>

###### Treated participants in the full analysis set and participants in the primary MMRM analysis (registry)

> “39 patients were treated and included in the Full Analysis Set (FAS). Enrollment, disposition and analyses are based on the FAS (n=39).”
> “Two patients were not considered in the MMRM analysis because not having any post-treatment HbA1c values available:”
> “Overall Number of Participants Analyzed 11 13 13”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.7.1-3"></a>

###### Enrolled participants and completers in the poster

> “The LEGEND trial enrolled 39 patients (33 completers) with MASH and type-2 diabetes (T2D), randomized 1:1:1 to lanifibranor (L), lanifibranor with empagliflozin (L+E) and placebo (P)”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="topic-3.1.3.7.1-4"></a>

###### Participants in the interim analysis

> “Since the interim analysis (IA) will include only the 32 patients that have already completed their 24-week treatment period at time of 31st Jan 2024, there will be no need to pre-define an unblinded team at Inventiva to review the statistical results of these 32 study-completed patients.”

Source: [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf)

> “As planned per protocol, the interim analysis was done once half of the 63 planned randomized patients with MASH completed the 24-week treatment period or prematurely discontinued from treatment.”
> “Two patients were not considered in the Full Analysis Set because we do not have post-treatment HbA1c values available”
> “Eight patients were not considered in the Completers set because of premature discontinuation before Week 24 or missing data due to prior intercurrent events (Rescue medication or significant diet modification affecting the primary endpoint).”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Analysis sets defined in the statistical analysis plan

> “The full analysis set (FAS) includes all randomized patients who received at least one dose of the assigned Investigational Medicinal Product (IMP), regardless of whether they prematurely discontinued randomized treatment or experienced any other intercurrent event, and meeting the targeted patient population of interest consistently with the primary estimand described in Section 12.5.2: Adults with non-cirrhotic NASH and T2DM defined by inclusion criteria No. 4 and 5 met, and exclusion criteria No. 2 and 15 not met.”
> “The Interim Analyis Set (IAS) consists of approximately the first half of the planned randomized patients from the FAS.”
> “The per protocol set (PPS) includes all patients in the FAS who do not have any major protocol deviations and who do not prematurely discontinue from treatment.”
> “The safety analysis set (SAS) includes all randomized patients who received at least one dose of IMP. Patients in the SAS will be analysed and summarized based on the treatment they actually received.”

Source: [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf)

<a id="topic-3.1.3.7.2-2"></a>

###### Hierarchical testing, type I error, and multiplicity in the protocol

> “A hierarchical fixed testing procedure for the primary endpoint tests will be used; lanifibranor alone will be compared to placebo at the 2-sided 0.05 level on the primary endpoint, and, should this test pass, the combination will be tested at the same level.”
> “The overall type I error of the study is 0.05 (2-sided). No alpha (type I error) adjustment will be considered for the interim analysis, i.e. still considering 0.05 (2-sided), this study being an exploratory proof-of-concept study.”
> “No multiplicity adjustment when testing for treatment effect on secondary/exploratory endpoints will be done. P-values will be considered exploratory.”

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf)

> “No multiplicity adjustments when testing for treatment effect on secondary endpoints.”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.7.2-3"></a>

###### Mixed model for repeated measures for the primary endpoint in the registry

> “To assess the superiority of each active arm versus placebo on absolute change in HbA1c from baseline, a mixed model for repeated measures (MMRM) was used with treatment group, time, treatment×time interaction as fixed effects, baseline HbA1c value and sex as covariates and the patient effect as a random effect.”
> “The MMRM was used to handle missingness because outcomes are measured repeatedly over time. No explicit imputation was done for missing data”

Source: [ClinicalTrials.gov NCT05232071 API record](https://clinicaltrials.gov/api/v2/studies/NCT05232071)

<a id="topic-3.1.3.7.2-4"></a>

###### Handling of intercurrent events in the poster

> “Parameters sensitive to pre-defined intercurrent events (initiation of significant diet change affecting metabolism [1 patient in L+E after TW12] and initiation of a rescue medication [1 patient before TW4 in L and 1 patient after TW12 in P]) were analyzed excluding data after the occurrence of the intercurrent event.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Participant flow by arm in the ClinicalTrials.gov results

> “Arm/Group Title Lanifibranor (800 mg/Day) Lanifibranor (800 mg/Day) Plus Empagliflozin (10mg/Day) Placebo”
> “Started 12 13 14”
> “Completed 12 12 9”
> “Not Completed 0 1 5”
> “Adverse Event 0 1 0”
> “Lost to Follow-up 0 0 2”
> “Non compliance with study drug 0 0 1”
> “Withdrawal by Subject 0 0 2”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.8.1-2"></a>

###### Screening and reasons for non-randomization in the ClinicalTrials.gov results

> “A total of 213 patients were screened for the study.”
> “Patients were invited to participate by their referent doctor based on their medical records. They had to fulfil all eligibility criteria. Main reason for non-randomization was screen failure.”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.8.1-3"></a>

###### Disposition by arm in the poster

> “Full analysis set 39 randomized and treated patients, 33 completed the 24-week treatment”
> “14 randomized and treated patients, 9 completed the 24-week treatment, 5 prematurely discontinued (2 withdrawal by patient, 2 lost to follow-up, 1 non-compliance with study drug)”
> “12 randomized and treated patients, 12 completed the 24-week treatment”
> “13 randomized and treated patients, 11 completed the 24-week treatment, 1 prematurely discontinued (AE)”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Demographics, glycemic stratum, and body size in the ClinicalTrials.gov baseline table

| Characteristic | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo | Total |
| --- | --- | --- | --- | --- |
| Participants | “12 participants” | “13 participants” | “14 participants” | “39 participants” |
| Age, years, mean (SD) | “55.1(11.45)” | “54.2(13.48)” | “54.7(13.01)” | “54.6(12.38)” |
| Female, n | “6” | “8” | “7” | “21” |
| White, n | “10” | “10” | “9” | “29” |
| Hispanic or Latino, n | “7” | “4” | “7” | “18” |
| HbA1c ≥7.5%, n | “8” | “8” | “9” | “25” |
| Weight, kg, mean (SD) | “93.30(11.614)” | “103.30(12.437)” | “94.50(21.269)” | “97.06(16.213)” |
| BMI, kg/m2, mean (SD) | “33.34(2.282)” | “37.62(4.300)” | “34.54(5.442)” | “35.19(4.554)” |

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.8.2-2"></a>

###### Median baseline characteristics in the poster

| Characteristic | Lanifibranor | Lanifibranor plus empagliflozin | Placebo | Total |
| --- | --- | --- | --- | --- |
| Age (years) | “55.5” | “54.0” | “55.5” | “55.0” |
| Sex (% female) | “6 (50)” | “8 (62)” | “7 (50)” | “21 (54)” |
| Country (% USA) | “11 (92)” | “12 (92)” | “12 (86)” | “35 (90)” |
| Weight (kg) | “93.9” | “99.9” | “97.4” | “97.2” |
| HbA1c (%) | “7.7” | “8.0” | “7.50” | “7.7” |
| ALT (U/L) | “53.0” | “52.0” | “33.0” | “39.0” |
| HOMA-IR | “9.4” | “10.9” | “16.3” | “10.8” |
| cT1 (ms) | “938” | “926” | “942” | “931” |
| MRI-PDFF (%) | “18.6” | “21.1” | “20.3” | “19.3” |

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Primary endpoint: absolute change in HbA1c from baseline to week 24, MMRM analysis (registry)

> “Two patients were not considered in the MMRM analysis because not having any post-treatment HbA1c values available:”
> “Least Squares Mean (95% Confidence Interval) | Unit of Measure: percentage of glycosylated hemoglobin”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

| Measure | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
| --- | --- | --- | --- |
| Participants analyzed | “11” | “13” | “13” |
| LS mean (95% CI) | “-1.11 (-1.6 to -0.62)” | “-1.54 (-2.02 to -1.06)” | “0.16 (-0.32 to 0.63)” |

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

| Comparison with placebo | LS mean difference | 95% CI lower limit | 95% CI upper limit | Standard error | p value |
| --- | --- | --- | --- | --- | --- |
| Lanifibranor 800 mg | “-1.27” | “-1.95” | “-0.58” | “0.33” | “< 0.001” |
| Lanifibranor 800 mg plus empagliflozin 10 mg | “-1.7” | “-2.38” | “-1.02” | “0.33” | “< 0.001” |

Source: [ClinicalTrials.gov NCT05232071 API record](https://clinicaltrials.gov/api/v2/studies/NCT05232071)

<a id="topic-3.1.3.8.3-2"></a>

###### Primary endpoint and HbA1c responders, FAS (poster)

> “Both L and L+E met the primary endpoint of HbA1c improvement versus P at TW24 (both p<0.001, FAS); 50% in both active arms reached HbA1c < 6.5% at TW24, with 58% and 80% HbA1c decrease ≥1% for L and L+E versus 0% for P, respectively.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="topic-3.1.3.8.3-3"></a>

###### HbA1c reduction and responders (company release, November 2024)

> “The study met the primary efficacy endpoint of HbA1c improvement with both treatment groups and patients treated with lanifibranor-only and in combination with empagliflozin showed a significant reduction in their HbA1c levels, with 50% of patients reaching an HbA1c under 6.5% by week 24 (p<0.001).”
> “Additionally, 58% of patients on lanifibranor alone and 80% of those on the combination therapy had a decrease of at least 1% in HbA1c at week 24, compared to 0% in the placebo group.”
> “November 15, 2024”

Source: [Inventiva LEGEND AASLD late-breaker release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Lanifibranor-AASLD-Late-Breaker-EN-11-15-2024.pdf)

<a id="topic-3.1.3.8.3-4"></a>

###### Primary endpoint and HbA1c responders at the interim analysis, FAS and completers (company release, March 2024)

> “today announces positive results of its interim analysis of the Phase II, Proof-of-Concept clinical trial, LEGEND”
> “The study achieved the primary efficacy endpoint with an absolute reduction in Hemoglobin A1c (HbA1c) of 1.14% and 1.59% in patients with MASH and T2D treated with lanifibranor (800mg daily) or in combination with empagliflozin (10mg daily) at week 24 compared to an increase of 0.26% observed in the placebo arm.”
> “Two patients were not considered in the Full Analysis Set because we do not have post-treatment HbA1c values available”
> “Eight patients were not considered in the Completers set because of premature discontinuation before Week 24 or missing data due to prior intercurrent events (Rescue medication or significant diet modification affecting the primary endpoint).”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

| Interim analysis measure | Placebo | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg |
| --- | --- | --- | --- |
| HbA1c, LS mean absolute change from baseline to week 24 (%), FAS | “0.26” | “-1.14” | “-1.59” |
| Participants, FAS | “(n=9)” | “(n=11)” | “(n=10)” |
| HbA1c <6.5% at week 24 (%), completers | “0” | “55” | “63” |
| HbA1c absolute decrease ≥1% at week 24 (%), completers | “0” | “64” | “88” |

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="topic-3.1.3.8.3-5"></a>

###### Hepatic steatosis by MRI-PDFF and cT1, LS mean change at week 24, FAS (poster)

> “Significant improvements of hepatic steatosis and composite MASH activity + fibrosis were observed for both L and L+E with mean relative MRI-PDFF changes of -49% (p=0.005) and -41% (p=0.02) and mean absolute cT1 changes of -86 and -75 ms respectively.”
> “LS mean relative change (%) from baseline to W24 in MRI-PDFF - FAS”
> “LS mean absolute change (ms) from baseline to W24 in cT1 - FAS”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="topic-3.1.3.8.3-6"></a>

###### Hepatic steatosis by MRI-PDFF at the interim analysis (company release, March 2024)

> “today announces positive results of its interim analysis of the Phase II, Proof-of-Concept clinical trial, LEGEND”
> “-47% and -38% respectively, compared to placebo (0%). 83% and 67% of patients treated with lanifibranor alone or in combination with empagliflozin respectively, showed a reduction greater or equal to 30% of their hepatic fat, compared to 0% in the placebo arm.”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="topic-3.1.3.8.3-7"></a>

###### Secondary endpoints at week 24, LS mean (95% CI), MMRM or ANCOVA (registry)

> “One patient under placebo was not considered in the MMRM analysis because no post-treatment values available (Premature discontinuation before Week 4)”
> “Sixteen patients were not considered in the ANCOVA analysis because of no VAT/SAT values available at Week 24:”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

| Outcome (unit) | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
| --- | --- | --- | --- |
| ALT, absolute change (U/L) | “-26.60 (-38.08 to -15.12)” | “-29.63 (-42.13 to -17.13)” | “-5.65 (-17.89 to 6.59)” |
| AST, absolute change (U/L) | “-13.67 (-20.66 to -6.68)” | “-17.81 (-25.5 to -10.12)” | “1.3 (-6.11 to 8.71)” |
| HOMA-IR, percentage change | “-50.79 (-95.69 to -5.89)” | “-45.23 (-89.86 to -0.61)” | “35.01 (-10.29 to 80.32)” |
| Insulin, percentage change | “-33.48 (-68.24 to 1.28)” | “-38.16 (-72.16 to -4.16)” | “10.17 (-23.63 to 43.96)” |
| Adiponectin, fold change | “2.87 (2.05 to 3.68)” | “3.03 (2.18 to 3.89)” | “1.24 (0.39 to 2.09)” |
| HDL cholesterol, relative change (%) | “16.48 (5.24 to 27.72)” | “15.30 (3.04 to 27.56)” | “2.55 (-9.76 to 14.86)” |
| VAT/SAT ratio, relative change (%) | “-4.6 (-14.44 to 5.25)” | “-17.45 (-28.67 to -6.23)” | “2.01 (-9.12 to 13.14)” |

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.8.3-8"></a>

###### Additional liver, fibrosis, inflammatory, and metabolic biomarkers, LS means at week 24 with p values (poster)

> “Liver tests (ALT, AST, GGT), fibrosis markers (TIMP-1, P3NP, Pro-C3), insulin, HOMA-IR, hs-CRP, ferritin, glycemia, lipid profile (HDL-C, Triglycerides) improved with L and L+E treatment, and adiponectin increased by a mean of 3-fold in both L and L+E arms compared to no increase for P.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

| LS mean at week 24 (p value versus placebo) | Lanifibranor | Lanifibranor plus empagliflozin | Placebo |
| --- | --- | --- | --- |
| GGT absolute change (IU/L) | “-21.9 (0.010)” | “-17.8 (0.015)” | “22.8” |
| TIMP-1 absolute change (ng/mL) | “-42.8 (0.040)” | “-40.0 (0.056)” | “-6.8” |
| Pro-C3 absolute change (ng/mL) | “-1.26 (0.120)” | “-3.54 (0.062)” | “7.33” |
| hs-CRP relative change (%) | “-32 (0.024)” | “-48 (0.008)” | “34” |
| Ferritin absolute change (µg/L) | “-78 (0.002)” | “-59 (0.022)” | “-8” |
| Glucose absolute change (mmol/L) | “-2.36 (0.005)” | “-1.98 (0.022)” | “-0.23” |
| Triglycerides relative change (%) | “-26 (0.006)” | “-27 (0.005)” | “-2” |

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

<a id="topic-3.1.3.8.3-9"></a>

###### Visceral to subcutaneous adipose tissue ratio and spleen volume, final analysis (poster) and interim analysis (company release)

> “The ratio VAT/SAT shifted favorably toward SAT for both L and L+E compared to placebo at TW24 (-5% and -17% vs +2%, respectively).”
> “Spleen volume decreased with L and L+E compared to placebo at TW24.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

> “today announces positive results of its interim analysis of the Phase II, Proof-of-Concept clinical trial, LEGEND”
> “Furthermore, these results demonstrated a significant relative reduction in the VAT/SAT ratio (visceral and subcutaneous adipose tissue) in patients treated with lanifibranor alone or in combination with empagliflozin, -5% and -17% respectively, compared to an increase of 11% in patients under placebo.”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="topic-3.1.3.8.3-10"></a>

###### Comparable effects of lanifibranor alone and with empagliflozin

> “The combination of lanifibranor with an SGLT2 inhibitor has comparable beneficial effects to lanifibranor alone on noninvasive hepatic and cardiometabolic markers of MASH, including a shift toward SAT, without observed weight gain.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

> “The improvement in cardiometabolic and hepatic markers of MASH was similar in both active treatment groups.”

Source: [Inventiva EASL SLD 2025 abstract release (2025)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-EASL-SLD-Abstract-01-22-2025.pdf)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Body weight, relative change from baseline to week 24, LS mean (95% CI) (registry)

> “Change in Body Weight and Body Composition (Body Weight)”
> “One patient under placebo was not considered in the MMRM analysis because of no post-treatment weight values available (premature discontinuation before Week 4)”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

| Measure | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
| --- | --- | --- | --- |
| Body weight, relative change (%) | “3.6 (2 to 5.19)” | “0.25 (-1.50 to 2.01)” | “-1.16 (-2.84 to 0.53)” |

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.8.5-2"></a>

###### Body weight with lanifibranor alone and with empagliflozin (poster and company release)

> “Patients had a mean weight increase of 3.6% with L at TW24, while mean weight remained unchanged in the L+E and placebo arms.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

> “Regarding weight, the lanifibranor-only group saw a small increase of 3.6%, while the weight remained stable in the group on lanifibranor and empagliflozin.”

Source: [Inventiva LEGEND AASLD late-breaker release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Lanifibranor-AASLD-Late-Breaker-EN-11-15-2024.pdf)

<a id="topic-3.1.3.8.5-3"></a>

###### Mortality, serious adverse events, and selected other adverse events by arm (registry)

> “On or after the first dose of treatment up to 30 days post last dose.”

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

| Event, affected / at risk (%) | Lanifibranor 800 mg | Lanifibranor 800 mg plus empagliflozin 10 mg | Placebo |
| --- | --- | --- | --- |
| All-cause mortality | “0/12 (0.00%)” | “0/13 (0.00%)” | “0/14 (0.00%)” |
| Other (not including serious) adverse events, total | “10/12 (83.33%)” | “9/13 (69.23%)” | “8/14 (57.14%)” |
| Serious adverse event: haematuria | “0/12 (0.00%)” | “1/13 (7.69%)” | “0/14 (0.00%)” |
| Anemia | “2/12 (16.67%)” | “0/13 (0.00%)” | “1/14 (7.14%)” |
| Oedema peripheral | “0/12 (0.00%)” | “1/13 (7.69%)” | “0/14 (0.00%)” |
| Headache | “2/12 (16.67%)” | “1/13 (7.69%)” | “0/14 (0.00%)” |
| Nausea | “1/12 (8.33%)” | “2/13 (15.38%)” | “0/14 (0.00%)” |
| Alopecia | “2/12 (16.67%)” | “0/13 (0.00%)” | “0/14 (0.00%)” |
| Diabetes mellitus inadequate control | “0/12 (0.00%)” | “2/13 (15.38%)” | “0/14 (0.00%)” |
| Blood glucose decreased | “0/12 (0.00%)” | “1/13 (7.69%)” | “1/14 (7.14%)” |

Source: [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results)

<a id="topic-3.1.3.8.5-4"></a>

###### Tolerability statements by the company

> “L and L+E were safe and well tolerated.”

Source: [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf)

> “The treatment with lanifibranor 800mg/daily alone and in combination with empagliflozin 10mg/daily for 24 weeks appears to be well tolerated, with no safety concerns reported.”

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary: sample size, early stop of recruitment, open-label arm, and multiplicity

- The protocol planned 63 participants (21 per group) for power close to 90%, assuming an HbA1c effect of 0.60% versus placebo. The protocol paused recruitment for an interim analysis once half of the planned participants were randomized; because the primary endpoint was met, recruitment was stopped. A total of 39 participants were treated (12 with lanifibranor, 13 with lanifibranor plus empagliflozin, and 14 with placebo) out of 213 screened.
- The lanifibranor and placebo arms were double-blind, and the lanifibranor plus empagliflozin arm was open-label.
- Treatment lasted 24 weeks, followed by a 4-week follow-up.
- No alpha adjustment was applied for the interim analysis, the protocol describing the trial as an “exploratory proof-of-concept study”, and no multiplicity adjustment was made for secondary endpoints.
- Inventiva does not expect to further study the combination of lanifibranor and empagliflozin.

Source: [Inventiva LEGEND protocol (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/Prot_000.pdf); [Inventiva LEGEND statistical analysis plan (2024)](https://cdn.clinicaltrials.gov/large-docs/71/NCT05232071/SAP_001.pdf); [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf); [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results); [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf); [Inventiva Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1756594/000110465926040704/iva-20251231x20f.htm)

<a id="topic-3.1.3.9-2"></a>

###### Summary: population, endpoints, missing data, and figures that differ by source

- MASH was diagnosed by historical histology or noninvasive methods, including cT1 thresholds on LiverMultiScan with or without MRI-PDFF. Participants had type 2 diabetes with HbA1c of 7.0% to 10.0% on diet, metformin, and/or a DPP-4 inhibitor; current or recent treatment with GLP-1 receptor agonists, insulin, or sulfonylureas was excluded. In the poster, 35 of 39 participants (90%) were enrolled in the United States.
- The primary endpoint was the change in HbA1c; other endpoints were circulating biomarkers and MRI-based imaging.
- In the placebo arm, 9 of 14 participants completed treatment (2 withdrawals, 2 lost to follow-up, 1 noncompliance). Two participants without post-treatment HbA1c values were excluded from the MMRM analysis, which used no explicit imputation, and 16 participants without week 24 VAT/SAT values were excluded from that ANCOVA analysis. Data after an intercurrent event (rescue medication in 2 participants and a significant diet change in 1) were excluded.
- The interim analysis (FAS, n=11, 10, and 9) reported HbA1c changes of -1.14% and -1.59% with lanifibranor and the combination versus +0.26% with placebo; the final registry analysis reports -1.11, -1.54, and 0.16. The VAT/SAT ratio with placebo increased by 11% in the interim release and by 2% in the final poster. Completers in the combination arm are 11 in the poster and 12 in the registry participant flow.

Source: [Inventiva LEGEND topline results release (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Results-LEGEND-EN-03-18-2024.pdf); [ClinicalTrials.gov NCT05232071](https://clinicaltrials.gov/study/NCT05232071); [Lai et al. (2024)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Poster-AASLD24-LEGEND.pdf); [ClinicalTrials.gov NCT05232071 results](https://clinicaltrials.gov/study/NCT05232071?tab=results); [ClinicalTrials.gov NCT05232071 API record](https://clinicaltrials.gov/api/v2/studies/NCT05232071)

<a id="heading-3.1.4"></a>

#### 3.1.4 NCT03459079

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Aims stated in the ClinicalTrials.gov brief summary

> “The primary aim is to establish the safety, efficacy and mechanism of action of lanifibranor in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). Specifically, to determine if lanifibranor decreases intrahepatic triglycerides (IHTG) (primary endpoint), improves hepatic insulin sensitivity, endogenous (hepatic) glucose production, de novo lipogenesis (DNL), HbA1c and lipid profiles.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.1-2"></a>

###### Aim stated in the published report

> “We tested its effect on insulin resistance (IR) at the level of different target tissues in relation to changes in intrahepatic triglyceride (IHTG) content.”
> “To this end, we examined the safety and efficacy of lanifibranor on intrahepatic triglyceride (IHTG) content and glucose/lipid metabolism using gold-standard imaging and metabolic measurements in patients with T2D and MASLD.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.1-3"></a>

###### Hypothesis stated in the protocol

> “This study will test the hypothesis that treatment with lanifibranor will significantly decrease liver steatosis (primary endpoint) in patients with T2DM and NAFLD.”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Study dates and location in the ClinicalTrials.gov record

> “Study Start (Actual) 2018-08-14”
> “Primary Completion (Actual) 2023-04-18”
> “Study Completion (Actual) 2023-06-01”
> “This study has 1 location”
> “Gainesville, Florida, United States, 32610”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.2-2"></a>

###### Results posting date in the ClinicalTrials.gov results

> “Results First Posted 2024-09-19”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.2-3"></a>

###### Site, recruitment sources, and enrollment period in the published report

> “The study was conducted at the University of Florida, Gainesville, Florida, in the United States and was approved by the Institutional Review Board.”
> “Participants were recruited from the general population of Gainesville, FL in response to newspaper and radio advertisements, or from the university endocrinology or primary care outpatient clinics (ClinicalTrials.gov identifier, NCT03459079).”
> “Between August 2018 and April 2023, 38 patients met the study eligibility criteria and were randomized to lanifibranor 800 mg/day (n = 20) or placebo (n = 18) and received at least one dose of study medication.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Single-center, double-blind, placebo-controlled design in the published report

> “This single-center study was a double-blind, parallel-group, placebo-controlled, 24-week trial in 38 individuals with T2D.”
> “Patients were randomized (1:1) to 24 weeks of treatment with either 800 mg of oral lanifibranor or placebo once daily (with no stratification factor).”
> “Masking (blinding) was achieved by generating tablets with identical appearance. Participants, people giving the interventions, those assessing outcomes, and those analyzing the data were masked to group assignment.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.3-2"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Interventional model description | “A two arm randomized (1:1), double-blind, placebo-controlled, trial.” |
| Masking | “Quadruple (ParticipantCare ProviderInvestigatorOutcomes Assessor)” |
| Phase | “Phase 2” |

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.3-3"></a>

###### Investigator-initiated design in the protocol

> “This study is a Phase II randomized, double-blind, placebo-controlled, single-center, investigator initiated, 24-week treatment study of lanifibranor in adult subjects with T2DM and NAFLD.”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

<a id="topic-3.1.4.3-4"></a>

###### Run-in, treatment, and follow-up periods in the ClinicalTrials.gov record

> “The study will last 34-36 weeks (~6-8 weeks for run-in, 24 weeks of treatment and 4 weeks post-study follow-up), with an estimated recruitment period of ~9 months.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.3-5"></a>

###### Visits and end-of-treatment assessments in the published report

> “Participants were followed monthly after randomization and monitored throughout the study.”
> “All baseline measurements were repeated at the end of treatment (EOT), including routine chemistries, liver MRI (performed 3 to 7 days before EOT) and the euglycemic hyperinsulinemic clamp (i.e. insulin sensitivity study) at week 24. A final visit for safety assessment occurred approximately 28 days after the last dose of study drug.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.3-6"></a>

###### Healthy control group for metabolic and imaging reference values

> “The study included a control group (n = 10, mean age 43 ± 18, 40% male, BMI 25.1 ± 3.3) of individuals without obesity, T2D or MASLD (<5% liver fat by 1H-MRS) to establish the normal range for the insulin sensitivity measurements.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

> “They are NOT treatment arms and participation ended after qualifying and the above studies.”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.3-7"></a>

###### Funding by Inventiva and role of the funder

> “Financial support provided by Inventiva Pharma.”
> “This study was designed by the principal investigator/corresponding author in agreement with and financially supported by Inventiva Pharma.”
> “The Research & Development [R&D] team at Inventiva Pharma had access to the database lock and assisted in the final analysis.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Key inclusion and exclusion criteria in the published report

> “Key participant inclusion criteria were T2D with an IHTG content ≥10% by liver 1H-MRS (proton magnetic resonance spectroscopy); fasting plasma glucose ≥100 and ≤250 mg/dl; hemoglobin A1c (HbA1c) between 6.0% [42.1 mmol/mol] and ≤9.5% [80 mmol/mol]), despite the use of metformin monotherapy at a stable dose of ≥1,000 mg/day, or combination therapy with metformin ≥1,000 mg/day and other agents, including DPP-4 inhibitors, sulfonylurea, SGLT2 inhibitors, and/or GLP-1RAs at stable daily doses (and with stable body weight) for at least 12 weeks prior to screening.”
> “Patients with liver conditions other than MASLD or taking medications that could promote steatosis were excluded.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.4-2"></a>

###### Key inclusion criteria in the ClinicalTrials.gov record

> “Have an age between 21 to 75 years inclusive”
> “Have uncontrolled diabetes with a fasting plasma glucose (FPG) ≥ 100 mg/dL but ≤ 250 mg/dL and HbA1c ≥ 6.0% but ≤ 9.5%, on diet alone, or on metformin (≥1,000 mg/day), and/or sulfonylurea and/or DPP-IV therapy, SGLT2 inhibitors or GLP1RA.”
> “Presence of hepatic steatosis (Intrahepatic Triglycerides IHTG) > 10 % determined by Magnetic Resonance and Spectroscopy (1H-MRS).”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.4-3"></a>

###### Key exclusion criteria in the ClinicalTrials.gov record: other liver disease, alcohol, insulin or pioglitazone, CYP2C8 interacting drugs, and BMI

> “Evidence of liver disease other than NAFLD.”
> “History of excessive alcohol intake, defined by ≥ 21 units of alcohol per week in males and ≥14 units of alcohol per week in females for two years prior to enrollment”
> “Patients on insulin, pioglitazone (or prior use in the past 12 months).”
> “Treatment with strong inducers or inhibitors of CYP2C8, or treatment with substrates of CYP2B6 or CYP2C8.”
> “Body mass index (BMI) > 45 kg/m2.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.4-4"></a>

###### Population not selected for fibrosis stage F2 or higher

> “Another consideration was that the study did not seek to recruit patients with”
> “MASH (fibrosis stage ≥F2) or assess the role of improving IR on liver histology”
> “Adding a liver biopsy before and after 6 months of treatment to the in-depth metabolic evaluations performed would have added an unacceptable level of complexity for participants.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Lanifibranor and placebo tablets in the ClinicalTrials.gov record

> “The film-coated tablet contains 400 mg of the active ingredient lanifibranor (IVA337) for an immediate release formulation. Participants receive 800mg/ day”
> “Film-coated tablets with a core containing 900 mg of a physical mixture of lactose monohydrate, microcrystalline cellulose, pre-gelatinized starch and magnesium stearate serve as placebo.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.5-2"></a>

###### Dose, administration with food, dose selection, and comparator in the protocol

> “The evaluated treatment will be as tablets of lanifibranor 400 mg, one dose of lanifibranor, 800 mg once a day (QD) versus placebo, i.e. two tablets (lanifibranor or indistinguishable placebo) per os, once daily, for 24 weeks. To improve bioavailability, drug intake is combined with food.”
> “The dose has been selected based on the available biomarker (adiponectin, HDL cholesterol, triglycerides) results in diabetes type 2 patients (Phase IIa study)”
> “Placebo is chosen as the comparator, as there is no licensed treatment for NAFLD/NASH.”
> “For obvious reasons, fibrates, as they are PPARα ligands, are not allowed, but dyslipidemias can be treated with statins, which are allowed.”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

<a id="topic-3.1.4.5-3"></a>

###### Background antidiabetic therapy and run-in titration in the ClinicalTrials.gov record

> “These medicines will be continued at stable doses during the entire study.”
> “Subjects with an HbA1c > 8.0% but ≤ 9.5% will have their metformin (minimum dose required: 1,000 mg/day) maximized to 1,000 mg BID and/or glimepiride 2 mg once daily added during the first 2 weeks of the run-in period.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Intrahepatic Triglyceride Content by Proton Magnetic Resonance Spectroscopy as the Primary Endpoint

<a id="topic-3.1.4.6.1-1"></a>

###### Primary endpoint as registered

> “Change in Intrahepatic Triglycerides (IHTG) Quantified by Proton Magnetic Resonance and Spectroscopy (¹H-MRS)”
> “Changes from baseline (Adjusted LS means) in absolute percent for change in intrahepatic triglycerides (IHTG) quantified by proton magnetic resonance and spectroscopy (¹H-MRS)are reported in each arms.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.6.1-2"></a>

###### Primary endpoint in the protocol and the published report

> “Primary outcome: Change in IHTG quantified by ¹H-MRS from baseline to 24 weeks”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

> “The primary endpoint of the study was the change in IHTG content measured by 1H-MRS from baseline to EOT.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.6.1-3"></a>

###### Proton magnetic resonance spectroscopy as the reference imaging method

> “The diagnosis of NAFLD on imaging will be done by measuring IHTG using the gold-standard magnetic resonance and spectroscopy (¹H-MRS) technique.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="topic-3.1.4.6.1-4"></a>

###### Thresholds for liver fat response and resolution and their assumed relation to histology in the protocol

> “reduction in liver fat by ¹H-MRS is empiric as there are no studies (except the Belfort et al, NEJM 2006 (1) and Cusi et al (2) with pioglitazone) comparing simultaneously ¹H-MRS data with liver histology, but it is assumed that such threshold is likely to correlate with positive histological changes in NASH, based on the investigator's experience.”
> “Proportion of patients considered as having resolution of NAFLD (≤5.5% IHTG quantified by 1H- MRS) at 24 weeks (highly likely to translate into histological benefit in NASH).”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

<a id="topic-3.1.4.6.1-5"></a>

###### Relation of steatosis to insulin resistance and to histological response in the published report

> “More importantly, steatosis is more strongly associated with IR than fibrosis in MASLD”
> “The ∼50% reduction in hepatic steatosis is consistent with the histological improvement reported in a prior 6-month study of identical duration”
> “The study focus was examining the role of panPPAR agonism on upstream metabolic aspects of the disease, and not liver histology for which it was not statistically powered.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.6.1-6"></a>

###### Secondary endpoints: insulin sensitivity by clamp, IHTG response, cardiometabolic parameters, and liver stiffness

> “The main prespecified secondary endpoint was the change in hepatic, muscle and adipose tissue insulin sensitivity using the gold-standard euglycemic hyperinsulinemic clamp technique to measure glucose turnover. Other secondary endpoints included changes in cardiometabolic parameters (i.e., HbA1c, lipid profile, adiponectin).”
> “Secondary outcomes included proportion of patients without steatosis after treatment (IHTG <5.5%) and proportion of patients with a ≥30% reduction in IHTG.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

> “Changes in Hepatic Fibrosis (Liver Stiffness Measurement by Vibration Controlled Transient Elastography in kPa) on Imaging.”
> “Changes in Hepatic Fibrosis (Liver Stiffness Measurement by Magnetic Resonance Elastography in kPa) on Imaging.”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Planned sample size revised on the basis of NATIVE steatosis results in the protocol

> “Version 2.4.1. Statistical analysis modified (number of patients reduced based on the results from NATIVE on steatosis [primary endpoint in this trial])”
> “In NATIVE, the proportion of patients with a reduction in steatosis to lanifibranor was 73% versus 26% with placebo (steatosis being the primary endpoint of this study)”
> “This represents a change of ≥7.0% with lanifibranor versus the control group. The expected standard deviation of the change from baseline is expected to be 7%.”
> “Considering a type I error of 0.05 (2-sided), a power of 0.80, an allocation ratio of 1:1, the same variance in both treatment groups and a parametric test of mean comparison, the required sample size per group is 15 patients to complete treatment.”
> “Assuming that 10 % of randomized patients will not complete the trial, the total number of patients to be randomized is 33-34 patients.”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

<a id="topic-3.1.4.7.1-2"></a>

###### Reduction of the planned number of participants stated in the ClinicalTrials.gov results

> “The original number of patients to be recruited was reduced during the trial based on the results of the NATIVE study (Francque et al, N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205), as explained in the study protocol.”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.7.1-3"></a>

###### Registry actual enrollment of 128 and 38 randomized participants

> “Enrollment (Actual) 128”

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079)

> “Of 128 total enrolled participants, 38 subjects with type 2 diabetes met inclusion criteria and were randomized to be treated. 10 healthy controls met inclusion criteria and completed imaging and other study assessments.”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.7.1-4"></a>

###### Randomized participants, full analysis set, and completers in the published report and the poster

> “Of the 38 individuals randomized, 28 completed the 24-week study (lanifibranor [n = 14, 70%] and placebo [n = 14, 78%]).”
> “Similar results were observed in a sensitivity analysis among completers [n = 28]”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

> “LS=Least Square, FAS=Full Analysis Set (n=38); Completers (n=28, 14 per group)”

Source: [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf)

<a id="topic-3.1.4.7.1-5"></a>

###### Randomized participants in the company topline release

> “The Phase II clinical trial randomized 38 patients into two arms, with patients receiving placebo or treatment with lanifibranor at 800mg/day for 24 weeks.”

Source: [Inventiva University of Florida trial topline release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Cusi-Lani-Topline-Results-EN-06132023-1.pdf)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Analysis sets defined in the protocol

> “The full analysis set consists of all randomized patients who received at least one dose of the assigned treatment.”
> “This set is the primary set of patients used in the primary analysis of the primary efficacy endpoint.”
> “The set of evaluable patients will consist of the FAS after exclusion of all patients who did not have an efficacy evaluation (IHTG) at week 24.”
> “This set is composed of all patients who completed the treatment and the study and who were free from major protocol deviation that can bias the estimation of the treatment effect at week 24.”
> “The safety set of patients will include all patients who have taken at least one dose of treatment (IVA 337 or placebo), regardless any protocol deviations.”

Source: [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf)

<a id="topic-3.1.4.7.2-2"></a>

###### Analysis sets, statistical tests, multiplicity, and missing data in the published report

> “Analyses were conducted on the full analysis set (FAS), including all randomized patients that received at least one dose of the assigned regimen.”
> “For statistical tests, the type I error risk was set at 5% (two-sided) in accordance with the protocol. No pre-specified plan was defined in the protocol to control for multiplicity adjustment for secondary or exploratory endpoints, which are considered exploratory.”
> “Categorical parameters were compared between treatment groups using Chi2 or Fisher’s exact tests.”
> “For the primary analysis, the primary rule for handling missing IHTG data at Week 24 was to use the baseline value at Week 24 if the mean change from baseline in the placebo group was equal to zero or was an improvement, or if the reason for missing data was definitely not related to treatment or disease progression.”
> “For categorical parameters, missing data were imputed as a failure.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### Participant flow by group in the ClinicalTrials.gov results

> “Arm/Group Title Lanifibranor Arm Placebo Healthy Control Group (Not a Treatment Arm)”
> “Started 20 18 10”
> “Completed 14 14 10”
> “Not Completed 6 4 0”
> “Adverse Event 4 2 0”
> “Withdrawal by Subject 2 2 0”
> “This study was performed during the epidemic of COVID that greatly impacted recruitment and promoted dropout.”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.8.1-2"></a>

###### Completion and reasons for discontinuation in the published report

> “Of the 38 individuals randomized, 28 completed the 24-week study (lanifibranor [n = 14, 70%] and placebo [n = 14, 78%]). Reasons for premature treatment discontinuation were adverse events (two participants in the placebo group and four in the lanifibranor group) and consent withdrawal (two in each group, during the COVID-19 pandemic).”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Baseline clinical and laboratory characteristics, FAS (published report)

> “Baseline clinical and laboratory characteristics (FAS, N = 38).”
> “Participants were well matched for age, gender, race, BMI; routine chemistries, glycemic control and baseline IHTG content were also well matched between the two groups.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

| Characteristic | Placebo (n = 18) | Lanifibranor (n = 20) |
| --- | --- | --- |
| Age, years (mean ± SD) | “58 ± 11” | “61 ± 7” |
| Gender (% male/female) | “28/72” | “45/55” |
| White, n (%) | “15 (83%)” | “18 (90%)” |
| Weight, kg (mean ± SD) | “99 ± 20” | “96 ± 14” |
| Body mass index, kg/m2 (mean ± SD) | “34.3 ± 6.2” | “33.8 ± 5.1” |
| Fasting plasma glucose, mg/dl (mean ± SD) | “122 ± 22” | “130 ± 26” |
| HbA1c, % (mean ± SD) | “7.0 ± 0.8” | “6.8 ± 0.5” |
| Fasting plasma insulin, μU/ml (mean ± SD) | “18.2 ± 12.7” | “16.4 ± 8.6” |
| Triglycerides, mg/dl (mean ± SD) | “196 ± 101” | “175 ± 95” |
| HDL-C, mg/dl (mean ± SD) | “43 ± 12” | “42 ± 9” |
| Alanine aminotransferase, U/L (mean ± SD) | “35 ± 27” | “37 ± 20” |
| Aspartate aminotransferase, U/L (mean ± SD) | “31 ± 19” | “31 ± 14” |
| HOMA-IR (mean ± SD) | “5.4 ± 3.4” | “5.6 ± 3.2” |
| Adiponectin, μg/ml (mean ± SD) | “5.0 ± 3.7” | “4.5 ± 2.8” |
| Intrahepatic triglyceride content, % (mean ± SD) | “18 ± 7” | “21 ± 7” |
| Liver stiffness by MRE, kPa (mean ± SD) | “2.5 ± 1.1” | “2.8 ± 0.8” |

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.2-2"></a>

###### Mean baseline HbA1c stated in the discussion of the published report

> “Most patients in this study had mild hyperglycemia (mean baseline HbA1c was 7.2%), so the full potential of lanifibranor to induce a greater glucose-lowering effect in patients with higher mean plasma glucose levels remains to be investigated.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.2-3"></a>

###### Baseline cT1, CAP, and LSM (poster)

> “CAP= Control Attenuation Parameter, LSM= Liver Stiffness Measurement.”

Source: [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf)

| Characteristic | Lanifibranor (N=20) | Placebo (N=18) |
| --- | --- | --- |
| Baseline corrected T1 mapping, ms | “887 ± 72” | “924 ± 116” |
| Baseline CAP, db/m | “356 ± 36” | “352 ± 28” |
| Baseline LSM, kPa | “8.3 ± 4.6” | “8.2 ± 7.2” |

Source: [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Primary endpoint: absolute change in IHTG at week 24, FAS and completers (published report)

> “The primary endpoint was met: treatment with lanifibranor was associated with a statistically significant absolute decrease in liver fat content (IHTG) by the end of the treatment period compared to placebo: FAS [n = 38]: -8.7% vs. -3.0%, respectively; least squares [LS] mean difference -5.6%, 95% CI -9.6 to -1.7%, p = 0.007 (Table 2, Fig. 2A). Similar results were observed in a sensitivity analysis among completers [n = 28] -10.8% vs. -4.0%; LS mean difference -6.9%, 95% CI -10.8 to -2.9%, p = 0.001 (Table 2, Fig. 2B).”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.3-2"></a>

###### Relative change in IHTG, IHTG reduction of at least 30%, and steatosis resolution, FAS and completers (published report)

> “The relative percent change in liver fat content significantly decreased more with lanifibranor compared to placebo (FAS [n = 38]: -44% vs. -12%, respectively; LS means difference -31%, 95% CI -51 to -12, p = 0.002) (Fig. 2C, Table 2).”
> “In completers [n = 28] (Fig. 2C, Table 2), the reduction in IHTG was -50% with lanifibranor vs. -16% with placebo (LS means difference -33%, 95% CI -53 to -14, respectively; p = 0.002).”
> “More patients achieved a ≥30% reduction in IHTG with lanifibranor compared to placebo (FAS 65% vs. 22%; completers 79% vs. 29%; both p <0.01, Fig. 2D, Table 2), as well as steatosis resolution (IHTG ≤5.5%) by the end of the treatment period (FAS 25% vs. 0%; completers 21% vs. 0%; both p <0.05, Table 2).”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.3-3"></a>

###### IHTG endpoints at week 24 (registry)

> “We report absolute change from baseline in LS mean [95% CI]”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

| Outcome | Lanifibranor (n = 20) | Placebo (n = 18) |
| --- | --- | --- |
| Absolute change in IHTG, LS mean (95% CI) | “-8.7 (-11.3 to -6.0)” | “-3.0 (-5.9 to -0.2)” |
| IHTG decrease of ≥30%, % of participants (95% CI) | “65 (41 to 85)” | “22 (6 to 48)” |
| NAFLD resolution (IHTG ≤5.5%), % of participants (95% CI) | “25 (9 to 49)” | “0 (0 to 19)” |

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.8.3-4"></a>

###### Secondary metabolic endpoints at week 24, FAS adjusted LS means (published report)

> “Effect of lanifibranor on metabolic parameters after 24 weeks of treatment.”
> “In the FAS, missing data were imputed using the last observation carried forward method.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

| Endpoint, FAS | Lanifibranor, adjusted LS mean [95% CI] | Placebo, adjusted LS mean [95% CI] | Adjusted LS mean difference [95% CI] | p value |
| --- | --- | --- | --- | --- |
| Fasting hepatic glucose production, relative change (%) | “-8 [-13; -4]” | “4 [-1; 9]” | “-13 [-20; -6]” | “<0.001” |
| Hepatic IR index, relative change (%) | “-26 [-37; -14]” | “-7 [-19; 4]” | “-18 [-34; -2]” | “0.04” |
| Insulin-stimulated muscle glucose disposal, relative change (%) | “30 [13; 46]” | “0 [-17; 18]” | “29 [5; 54]” | “0.02” |
| Fasting plasma insulin, absolute change (μU/ml) | “-3.1 [-5.5; -0.8]” | “-0.0 [-2.5; 2.5]” | “-3.1 [-6.5; 0.3]” | “0.07” |
| Fasting plasma glucose, absolute change (mg/dl) | “-17.2 [-27.4; -7.0]” | “2.4 [-8.4; 13.2]” | “-19.6 [-34.5; -4.7]” | “0.01” |
| HOMA-IR, absolute change | “-1.6 [-2.5; -0.7]” | “-0.1 [-1.1; 0.8]” | “-1.5 [-2.8; -0.2]” | “0.03” |
| Adipo-IR, absolute change | “-2.7 [-4.3; -1.2]” | “-0.7 [-2.4; 0.9]” | “-2.0 [-4.2; 0.3]” | “0.08” |
| HbA1c, absolute change (%) | “-0.7 [-1.0; -0.5]” | “-0.1 [-0.3; 0.2]” | “-0.6 [-1.0; -0.5]” | “<0.001” |
| HDL-C, absolute change (mg/dl) | “7.6 [4.4; 10.7]” | “0.9 [-2.4; 4.3]” | “6.6 [2.0; 11.3]” | “0.006” |
| Adiponectin, fold change | “2.4 [2.0; 2.7]” | “1.0 [0.6; 1.4]” | “1.4 [0.9; 1.9]” | “<0.001” |

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.3-5"></a>

###### Hepatic glucose production and muscle glucose disposal, completers (published report)

> “Among completers, the mean ± standard error fasting HGP decreased significantly with lanifibranor from 3.98 ± 0.23 to 3.34 ± 0.19 mg/kg/min compared to an increase with placebo (3.69 ± 0.23 to 3.87 ± 0.18 mg/kg/min), with a mean relative difference vs. placebo at week 24 of -16%, p <0.001 (Table 2, Fig. 3A).”
> “Tissue Rd increased by approximately 45% with lanifibranor compared to placebo (LS means difference 45%, 95% CI 12 to 77; Table 2, Fig. 3C).”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.3-6"></a>

###### Liver stiffness by transient elastography and MRE and plasma cytokeratin-18 at week 24 (registry)

> “Two subjects in the lanifibranor group missing this measurement due to technical errors”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

| Outcome | Lanifibranor | Placebo |
| --- | --- | --- |
| Liver stiffness by vibration controlled transient elastography, absolute change in kPa, LS mean (95% CI); n = 20 and 18 | “-1.49 (-2.66 to -0.31)” | “-0.34 (-1.57 to 0.9)” |
| Liver stiffness by MRE, change in kPa, LS mean (95% CI); n = 18 and 18 | “0.23 (0.03 to 0.42)” | “-0.06 (-0.25 to 0.13)” |
| Plasma cytokeratin 18, absolute change in IU/L, mean (SD); n = 20 and 18 | “-130.71(164.28)” | “-70.21(230.39)” |

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

> “The trend in improvement of steatohepatitis disease activity by liver cT1 and liver stiffness measurement was consistent with NATIV2 (Table S3).”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.3-7"></a>

###### Primary endpoint as reported in the 2023 congress poster, FAS and completers

> “Late Breaking Poster Abstract # 48475 at The Liver Meeting 2023, Boston, MA, USA”
> “Figure 3: Lanifibranor compared to placebo significantly lowered IHTG at EOT: in FAS the absolute change in IHTG as -10.1% in lanifibranor vs. -1.4% in placebo; least squares [LS] means difference -5.6%, [95% CI -9.6 to -1.7%], p=0.007; completers -12.4% vs. -2.4%; LS means difference -6.9%, [95% CI -10.8 to -2.9%], p=0.001 (Figure 3A and 3B).”

Source: [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf)

<a id="topic-3.1.4.8.3-8"></a>

###### Topline results, FAS and completers (company release, June 2023)

> “Lanifibranor 800mg achieved the primary efficacy endpoint demonstrating a 44% reduction of hepatic fat measured by proton magnetic resonance spectroscopy (1H-MRS) following 24 weeks of treatment in patients with nonalcoholic fatty liver disease (NAFLD).”
> “The study demonstrated a statistically significant higher proportion of patients achieving a greater than 30% liver triglyceride reduction (65% vs. 22%, p =0.008) as well as NAFLD resolution (25% vs. 0%, p = 0.048) defined as IHTG ≤ 5.5% at week 24, with lanifibranor compared to placebo.”
> “Full Analysis Set (N=38)”
> “Completers (N=28)”
> “June 13, 2023”

Source: [Inventiva University of Florida trial topline release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Cusi-Lani-Topline-Results-EN-06132023-1.pdf)

| Completers, change from baseline to week 24 | Placebo (n=14) | Lanifibranor 800 mg (n=14) |
| --- | --- | --- |
| Absolute change in HbA1c, % | “-0.2%” | “-0.9” |
| Absolute change in fasting plasma insulin, μU/ml | “-1.0” | “-6.7” |
| Absolute change in hepatic insulin resistance index | “-9.5” | “-30.1” |
| Absolute change in basal endogenous glucose production (mg/kgLBM/min) | “0.1” | “-0.5” |
| Absolute change in muscle insulin-stimulated glucose disposal (mg/kg LBM/min) | “-0.2” | “+2.2” |
| Absolute change in HDL-C, mg/dl | “-0.3” | “6.3” |
| Absolute change in adiponectin, μg/mL | “-0.2” | “7.5” |

Source: [Inventiva University of Florida trial topline release (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/Inventiva-PR-Cusi-Lani-Topline-Results-EN-06132023-1.pdf)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Weight gain, adverse events, and discontinuations (published report)

> “Compared to placebo, lanifibranor caused weight gain (Fig. S5). Mean weight gain was +2.7% under lanifibranor compared to -1.0% on placebo at the end of the treatment period.”
> “Adverse events were mostly mild (anemia and gastrointestinal side effects) and balanced between groups. Six patients prematurely discontinued study drug due to adverse events (Table 3). One serious adverse event (COVID-19 infection and hospitalization with pulmonary embolism) occurred under lanifibranor but was unrelated to study drug.”
> “Five were drug-related treatment-emergent adverse events: two in the placebo group (one severe elevation in plasma aminotransferases of unknown etiology, another an asymptomatic elevation of lipase level), and three in the lanifibranor group: asymptomatic elevation of lipase level (n = 1), leukopenia (n = 1) and drug intolerance (nausea, headache, loose stools, atypical chest pain).”
> “Lanifibranor was safe and well tolerated, with no patient developing a drug-related serious adverse event.”

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.5-2"></a>

###### Treatment-emergent adverse events by group (published report)

| Event, n (%) | Placebo (n = 18) | Lanifibranor (n = 20) |
| --- | --- | --- |
| Patients with TEAEs | “17 (94%)” | “18 (90%)” |
| Patients with severe TEAEs | “0 (0%)” | “1 (5%)” |
| Patients with serious adverse events | “0 (0%)” | “1 (5)” |
| TEAEs leading to drug discontinuation | “2 (11%)” | “4 (20%)” |
| Drug-related TEAE leading to discontinuation | “2 (11%)” | “3 (15%)” |
| Diarrhea | “3 (17%)” | “5 (25%)” |
| Elevated lipase level | “3 (17%)” | “5 (25%)” |
| Anemia | “2 (11%)” | “4 (20%)” |
| Leukopenia | “1 (6%)” | “3 (15%)” |
| Headache | “1 (6%)” | “3 (15%)” |
| Arthralgia | “3 (17%)” | “0 (0%)” |
| Oedema | “0 (0%)” | “1 (5%)” |
| Hypoglycemia | “0 (0%)” | “1 (5%)” |
| Decrease in eGFR | “2 (11%)” | “1 (5%)” |

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext)

<a id="topic-3.1.4.8.5-3"></a>

###### Weight change in kilograms, edema, hemoglobin, and lipase (poster)

> “Compared to placebo, lanifibranor caused weight gain of +2.7% (+2.5 ± 3.1 kg vs -1.2 ± 2.6 kg in placebo, p=0.002) and in 1 patient mild edema.”
> “Changes in hemoglobin levels by week 24 were mild.”
> “Although elevated lipase was reported more commonly in lanifibranor group, none were associated with clinical symptoms.”

Source: [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf)

<a id="topic-3.1.4.8.5-4"></a>

###### Mortality, serious adverse events, and selected other adverse events over 28 weeks (registry)

> “Time Frame 28 weeks”

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

| Event, affected / at risk (%) | Lanifibranor | Placebo |
| --- | --- | --- |
| All-cause mortality | “0/20 (0.00%)” | “0/18 (0.00%)” |
| Serious adverse events, total | “1/20 (5.00%)” | “0/18 (0.00%)” |
| Other (not including serious) adverse events, total | “18/20 (90.00%)” | “17/18 (94.44%)” |
| Anaemia | “4/20 (20.00%)” | “2/18 (11.11%)” |
| Diarrhoea | “5/19 (26.32%)” | “3/18 (16.67%)” |
| Elevated lipase level | “5/20 (25.00%)” | “3/18 (16.67%)” |
| Edema | “1/20 (5.00%)” | “0/18 (0.00%)” |

Source: [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary: design, sample size, and enrolled population

- The trial was single-center (Gainesville, Florida) and investigator-initiated, with financial support from Inventiva; the Inventiva research and development team had access to the database lock and assisted in the final analysis.
- The planned number of participants was reduced during the trial on the basis of NATIVE steatosis results, to 15 per group completing treatment (power 0.80) and 33 to 34 randomized. A total of 38 participants were randomized (20 lanifibranor, 18 placebo), and 28 completed 24 weeks (14 [70%] and 14 [78%]). The registry states that the COVID epidemic greatly impacted recruitment and promoted dropout. The registry enrollment of 128 counts all enrolled participants, of whom 38 were randomized and 10 were healthy controls.
- The registry gave an estimated recruitment period of about 9 months; randomization took place between August 2018 and April 2023.
- The authors state that the study did not seek to recruit patients with MASH (fibrosis stage ≥F2) or to assess the role of improving insulin resistance on liver histology, for which the study was “not statistically powered”. The protocol states that the liver fat thresholds are assumed to correlate with histological changes based on the investigator's experience.
- The discussion of the published report describes mild hyperglycemia with a mean baseline HbA1c of 7.2%; the baseline table gives 7.0 ± 0.8% with placebo and 6.8 ± 0.5% with lanifibranor. The male/female percentages at baseline were 28/72 with placebo and 45/55 with lanifibranor.

Source: [ClinicalTrials.gov NCT03459079](https://clinicaltrials.gov/study/NCT03459079); [University of Florida lanifibranor protocol (2022)](https://cdn.clinicaltrials.gov/large-docs/79/NCT03459079/Prot_SAP_000.pdf); [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext); [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

<a id="topic-3.1.4.9-2"></a>

###### Summary: missing-data handling, multiplicity, and figures that differ by source

- For missing week 24 IHTG data, the primary analysis used the baseline value under stated conditions; missing categorical data were imputed as failure, and missing data for the secondary metabolic endpoints were imputed by last observation carried forward.
- The protocol defined no plan to control multiplicity for secondary or exploratory endpoints, which are considered exploratory.
- The absolute change in IHTG differs by source. The 2023 congress poster reports -10.1% with lanifibranor versus -1.4% with placebo in the FAS and -12.4% versus -2.4% in completers; the published report gives -8.7% versus -3.0% (FAS) and -10.8% versus -4.0% (completers), and the registry gives -8.7 and -3.0. Both the poster and the published report give LS mean differences of -5.6% (FAS) and -6.9% (completers).

Source: [Barb et al. (2025)](https://www.journal-of-hepatology.eu/article/S0168-8278%2825%2900002-9/fulltext); [Barb et al. (2023)](https://inventivapharma.com/wp-content/uploads/inventiva-documents/AASLD-abstract-3.pdf); [ClinicalTrials.gov NCT03459079 results](https://clinicaltrials.gov/study/NCT03459079?tab=results)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
